[STUDY_ID_REMOVED]    
 
Study ID: 201025‐001  
 
 
Title: A Multicenter,  Randomized,  Double‐blind, Placebo‐controlled  Study, Evaluating  Safety and Efficacy 
of LiRIS® 400 mg in Females With Interstitial  Cystitis With Hunner’s  Lesions 
  
Protocol Amendment  2 Date: 28‐Apr‐2016 
 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 1 GDD-TA-T-004 v2013.9 
 Title Page 
ALLERGAN – CONFIDENTIAL 
The following contains confidential, proprietary information 
which is the property of Allergan 
 
STUDY TITLE 
A Multicenter, Randomized, Double-blind, Place bo-controlled Study, Evaluating Safety and 
Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner’s Lesions 
 
Protocol Number:   201025-001 Amendment 2 
Phase: [ADDRESS_1015086]: LiRIS® (Lidocaine-releasing intravesical system) 
Sponsor: 
 Allergan (North America) 
[ADDRESS_1015087] Irvine, [LOCATION_004] [LOCATION_003] [ZIP_CODE] +[PHONE_10421] 
+[PHONE_10422]   
Emergency Telephone Number(s): 
Refer to the Study Contacts Page.   
 
  
   
 
  
  
 
 
 
Refer to 
the final page of this protocol for electronic 
signature [CONTACT_51472]. 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 2 GDD-TA-T-004 v2013.9 
 The following information can be found on FDA Form 1572 and/or study contacts page:  
Name [CONTACT_3669] [CONTACT_687966]; name, address, and statement of quali fications of each invest igator; name [CONTACT_687985]; name [CONTACT_287472]; name [CONTACT_160489]; US 21 CFR 312.23 
section 6(iii)b. 
 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 3 GDD-TA-T-004 v2013.9 
 INVESTIGATOR SIGNATURE [CONTACT_249625]:  
  
 
I agree to: 
• Implement and conduct this study diligently a nd in strict compliance with the protocol, 
good clinical practices and all ap plicable laws and regulations. 
• Maintain all information supplied by [CONTACT_249595], when this information 
is submitted to an Institutional Review Board (IRB), Independent Ethics Committee 
(IEC) or another group, it will be submitted with a designation that the material is 
confidential. 
• Ensure that all persons assisti ng with the trial are adequately informed about the protocol, 
the investigational product(s), and their trial- related duties and functions. 
I have read this protocol in its en tirety and I agree to all aspects. 
     
Investigator Printed Name  [CONTACT_535417] :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015088]........................................................................................... 21 
1.3 Nonclinical Studies ................................................................................................ 22  
1.4 Clinical Studies ...................................................................................................... 22  
2. Study Objective and Clinical Hypothesis ........................................................................ 24  
2.1 Study Objective ...................................................................................................... 24  
2.2 Clinical Hypotheses ............................................................................................... 24  
3. Study Design .................................................................................................................. .. 24 
4. Study Population and Entry Criteria ................................................................................ 25  
4.1 Number of Patients ................................................................................................. 25  
4.2 Study Population Characteristics ........................................................................... 25  
4.3 Inclusion Criteria .................................................................................................... 25  
4.4 Exclusion Criteria................................................................................................... 27  
4.5 Permissible and Prohibited Medications/Treatments ............................................. 29  
4.5.1 Permissible Medicati ons/Treatments ......................................................... 29  
4.5.2 Prohibited Medications/Treatments ........................................................... 30  
4.5.3 Rescue Medications ................................................................................... 31  
4.5.4 Oral Prophylactic Antibiotics ..................................................................... 32  
4.5.5 Study Treatment Anesthesia ....................................................................... 32  
4.5.6 Special Diet or Activities ........................................................................... 32  
5. Study Treatments ............................................................................................................. 33 
5.1 Study Treatments and Formulations ....................................................................... 33  
5.2 Control Treatment .................................................................................................. 33  
5.3 Methods for Masking/Blinding .............................................................................. 33  
5.4 Treatment Allocation Ratio and Stratification........................................................ 33  
5.5 Method for Assignment to Treatment Groups/Randomization .............................. 34  
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 5 GDD-TA-T-004 v2013.9 
 5.6 Treatment Regimen and Dosing ............................................................................. 34  
5.6.1 Treatment 1 ................................................................................................ 34  
5.6.2 Treatment 2 ................................................................................................ 34  
5.6.3 Premature IP Removal ............................................................................... 34  
5.7 Storage of Study Medications/Treatments ............................................................. [ADDRESS_1015089] Events .................................... 39  
6.5 Examination Procedures, Tests, Equipment, and Techniques ................................ 39  
6.5.1 Medical History/Demographics ................................................................. [ADDRESS_1015090]-use Assessment .................................................................................. 43  
6.5.12 Bladder Pain NRS ...................................................................................... 43  
6.5.13 Bladder Diary ............................................................................................. 44  
6.5.14 Pain Catastrophizing Scale ......................................................................... 44  
6.5.18 Concomitant Medications and Concurrent Procedures .............................. 45  

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 6 GDD-TA-T-004 v2013.9 
 6.5.19 Adverse Events .......................................................................................... 46  
6.5.20 IP Events .................................................................................................... 46  
6.6 Other Study Supplies .............................................................................................. 47  
6.7 Summary of Methods of Data Collection .............................................................. 47  
7. Statistical Procedures ....................................................................................................... 48 
7.1 Analysis Populations .............................................................................................. 48  
7.2 Collection and Derivation of Primary, Secondary, and Other Efficacy Assessments
 .............................................................................................................................. .. 48 
7.2.1 Primary Efficacy Variables ......................................................................... 49  
7.2.2 Secondary Efficacy Variables ..................................................................... 49  
   
7.3 Hypothesis and Methods of Analysis ..................................................................... 51  
7.3.1 Demographics, Baseline Characteris tics and Disposition Analyses .......... 52  
7.3.2 Efficacy Analyses ....................................................................................... 52  
7.3.3 Safety Analyses .......................................................................................... 54  
7.4 Pharmacokinetic Analysis ...................................................................................... 56  
7.5 Missing Data .......................................................................................................... 56  
7.6 Subgroup Analyses ................................................................................................. 56  
7.7 Sample Size Calculation ........................................................................................ 56  
7.8 Interim Analyses..................................................................................................... 57  
8. Study Visit Schedule and Procedures .............................................................................. 57  
8.1 Patient Entry Procedures ........................................................................................ 57  
8.1.1 Overview of Entry Procedures ................................................................... 57  
8.1.2 Informed Consent and Patient Privacy ....................................................... 57  
8.2 Procedures for Final Study Entry ........................................................................... 58  
8.3 Visits and Associated Procedures ........................................................................... 58  
8.4 Instructions for the Patients .................................................................................... 58  
8.5 Unscheduled Visits ................................................................................................. 59  
8.6 Compliance With Protocol ..................................................................................... 59  
8.7 Early Discontinuation of Patients .......................................................................... 59  
8.8 Withdrawal Criteria ................................................................................................ 59  
8.9 Study Termination .................................................................................................. 60  
9. Adverse Events ................................................................................................................  60 
9.1 Definitions .............................................................................................................. 60  

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015091] or Study Procedure ........... 62  
9.2 Procedures for Reporting Adverse Events ............................................................. 62  
9.3 Procedures for Reporting a Serious Adverse Event ............................................... 62  
9.4 Procedures for Unblinding of Study Medication ................................................... 63  
10. Administrative Items ....................................................................................................... 64  
10.1 Protection of Human Patients ................................................................................ 64  
10.1.1 Compliance With Informed Consent Regulations (US 21 Code of Federal 
Regulations [CFR] Part 50) and Re levant Country Regulations ............... 64  
10.1.2 Compliance With IRB or IEC Regulations ................................................ 64  
10.1.3 Compliance With Good Clinical Practice .................................................. 64  
10.1.4 Compliance With Electronic Records;  Electronic Signatures Regulations 
(US 21 CFR Part 11) .................................................................................. 64  
10.2 Changes to the Protocol ......................................................................................... 65  
10.3 Patient Confidentiality ........................................................................................... 65  
10.3.1 Patient Privacy ........................................................................................... 65  
10.4 Documentation ....................................................................................................... 65  
10.4.1 Source Documents ..................................................................................... 65  
10.4.2 Case Report Form Completion................................................................... 66  
10.4.3 Study Summary .......................................................................................... 67  
10.4.4 Retention of Documentation ...................................................................... 67  
10.5 Labeling, Packaging, and Return or Dis posal of Study Medications/Treatments .. 67  
10.5.1 Labeling/Packaging .................................................................................... 67  
10.5.2 Clinical Supply Inventory .......................................................................... 68  
10.5.3 Return or Disposal of Study Medica tions/Treatments and/or Supplies ..... 68  
10.6 Monitoring by [CONTACT_1034] .................................................................................... 68  
10.7 Handling of Biological Specimens......................................................................... 68  
10.8 Publications ............................................................................................................ 69  
10.9 Coordinating Investigator ...................................................................................... 69  
11. References .................................................................................................................... .... 69 
12. Attachments ................................................................................................................... .. 73 
12.1 Questionnaires ........................................................................................................ 74  
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015092] of Tables 
Table 1  Schedule of Visits and Procedures .................................................................. 16  
Table 2  Summary of IC Medication/Thera py Requirements in the Study................... [ADDRESS_1015093] of Figures 
Figure 1  Flow Chart of Study Visits .............................................................................. 15  
 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 9 GDD-TA-T-004 v2013.9 
 Protocol Summary 
 
Study Compound(s):  LiRIS® (Lidocaine-releasing intrav esical system) AGN-201025 
Phase:  2 
Study Objective:  To evaluate the safety and efficacy of a 28-day  period of continuous  release of lidocaine 
inserted into the bladder utilizing 2 consecutive LiRIS 400 mg comp ared with placebo fo r the treatment and 
corresponding symptoms of interstitial cystitis (IC) with Hunner’s Lesions (HL) in female patients 
Clinical Hypotheses:  A 28-day period of continuous release of lidocaine inserted into the bladder utilizing 
[ADDRESS_1015094] an  acceptable safety profile and is mo re efficacious than placebo for the 
treatment and corresponding symptoms of IC with HL in female patients 
Study Design 
Structure :  Multicenter, randomized, doub le-blind, placebo-controlled study  
Duration :   
For patients who participate in the study and receive  only one treatment, the duratio n of study participation will 
be 28 weeks.  For patients who qualify and receive Tr eatment 2 (active LiRIS only), the minimum duration of 
participation is 16 weeks and the maximum duration of study participation is 36 weeks 
Study Treatment Groups :   
1) LiRIS 400 mg, LiRIS 400 mg (Treatment 1 Period)/LiRIS 400 mg (Treatment 2 Period) 
2) LiRIS Placebo, LiRIS Placebo (Treatment 1 Pe riod)/LiRIS 400 mg (Treatment 2 Period) 
3) LiRIS Placebo, LiRIS 400 mg (Treatment 1 Period)/LiRIS 400 mg (Treatment 2 Period) 
Controls :  LiRIS Placebo 
Dosage/Dose Regimen:  
Treatment 1 Period (Tx 1): 
Treatment 1 includes the following:  2 consecutive Li RIS 400 mg, 2 consecutive Li RIS Placebo, or one LiRIS 
Placebo followed by [CONTACT_742620] 400 mg  
Treatment 2 Period (Tx 2): 
One LiRIS 400 mg Randomization/Stratification :  Randomization will be centralized and stratified by [CONTACT_742621] ( ≤ 5 or 
> 5) collected during the Screening period.  Each patient within a stratum will be randomized to one of 3 groups 
(2 consecutive LiRIS 400 mg or 2 consecutive LiRIS Placebo or one LiRI S Placebo followed by [CONTACT_742622] 400 mg) in a 2:1:1 ratio that will define the patient’s assignment in Treatment 1. 
Visit Schedule :   
Treatment 1: 
Patients will be evaluated during the Screening period for eligibility. 
Eligible patients will be: 
     
      
    
    

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 10 GDD-TA-T-004 v2013.9 
   
   
  
 
 
 
 
 
   
   
  
  
Stud
y Population Characteristics 
Number of Patients :  Approximately 76 patients will be enrolled into the study to ensure 72 evaluable patients 
overall for Treatment 1, including 36 patients in the LiRIS 400 mg/LiRIS 400 mg group, 18 patients in the 
LiRIS Placebo/LiRIS Placebo group, and 18 patients in the LiRIS Placebo/LiRIS 400 mg group. 
Condition/Disease :  Female patients with IC with HL   
Key Inclusion Criteria :   
• females ≥  18 years of age  
• a diagnosis of IC with HL defined as: 
o an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary 
bladder, associated with lower urinary tract  symptoms (LUTS) of more than 6 months 
duration in the absence of infection or other identifiable causes (van de Merwe et al, 2008), 
documented history or patient reported 
and 
o documented history of an observation of HL via cystoscopic procedure in which a lesion is 
defined as a circumscript, reddened mucosal area that can be small vessels radiating towards a 
central scar, and/or a fibrin deposit of coagulum  attached to this area.  Lesions may also be 
linear, fissure-like, and may be bleeding. 
•  
 
  
 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 11 GDD-TA-T-004 v2013.9 
   
  
  
 
  
 
 
 
See Section 4.3 for detailed inclusion criteria 
Key Exclusion Criteria :   
•  
  
 
  
  
 
 
  
 
 
 
See Sect i
on 4.4 for detailed exclusion criteria. 
Response Measures 
Efficacy:  
Primary:  
• average daily bladder pain score patient experienced over the previous 24-hour period as measured by [CONTACT_742623] 0 to 10, recorded on a 7-day pain assessment tool   
 
The primary timepoint is Week 4 following Treatment 1 2nd IP removal. 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 12 GDD-TA-T-004 v2013.9 
 Secondary: 
• number of HLs assessed by [CONTACT_079] (PI) during cystoscopy 
• composite score of HL calculated based on number, size, and severity of the lesions  
  
  
 
  
  
 
  
  
 
    
  
   
  
 
  
   
  
 
   
  
Safety:   
• a
dverse events and serious adverse events  
• physical examination 
• vital signs 
• any abnormal cystoscopy findin gs at insertion and removal 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 13 GDD-TA-T-004 v2013.9 
 • pregnancy testing for women of childbearing potential 
• urine dipstick reagent test 
• urine analysis (with urine culture and sensitivity, as applicable) 
• urine cytology (at Screening only) 
• post-void residual (PVR) urine volume measurement  
• hematology and non-fasting serum chemistry 
• concomitant medications 
• concurrent procedures 
Post-use Assessments and IP events 
• voiding of the IP  
• damage to the IP during insertion or removal procedures 
• damage to the IP that is not related to insertion or removal procedures 
General Statistical Methods and Types of Analyses:    
Modified intent-to-treat (mITT) analysis population:  The mITT population will include all patients who were 
randomized and received at le ast 1 IP insertion in Treatment 1.  Th e efficacy data w ill be analyzed as 
randomized using the mITT population.  
Safety analysis population:  The safety population will include all patients enrolled in this study and received at 
least one IP.  The safety data will be analy zed as treated using the safety population. 
Pharmacokinetic evaluable population:  The pharmacokinetic population will include all patients enrolled in this study and who have at least one plasma or urine pharmacokinetic concentration measurement post-IP insertion and for whom the IP is successfully removed. 
Per-protocol (PP) analysis population:  The PP populatio n will include all patients who retain the [ADDRESS_1015095] patient has completed the primary timepoint 
(Week 4 following removal of the Treatment 1 2nd IP).  The objective of the primary analysis is to support 
further development of this program in this indication.  The final analysis will be conducted when all patients complete or exit the study. 
All continuous variables will be summarized showing the number of observations, mean, median, standard 
deviation, minimum, and maximum values.  Discrete variables will be summarized showing the frequency and percentage of the study population.  Visual display of efficacy data (value and/or change from baseline) may be 
presented over time. 
The primary efficacy variable will be  analyzed using the analysis of covariance (ANCOVA) model using the 
baseline value as the covariate, and stratifi cation factor (baseline bladder pain NRS:  ≤ 5 or > 5) and treatment 
as factors.  Similar ANCOVA analyses will  be used for secondary efficacy analyses. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 14 GDD-TA-T-004 v2013.9 
 Sample Size Calculation :  Approximately 76 patients will be enrolled into the study.  Assuming that 5% of the 
randomized patients will not be evaluable for the primary anlysis, this will ensure 72 evaluable patients overall, 
including 36 patients in the LiRIS 400 mg/LiRIS 400  mg group, 18 patients in the LiRIS Placebo/LiRIS 
Placebo group, and 18 pa tients in the LiRIS Placebo/LiRIS 400 mg group. 
A sample size of 36 patients in the LiRIS 400 mg/LiRIS 400 mg group versus 18 patients in the Placebo/Placebo group  will have 76% power to detect a difference of 1.[ADDRESS_1015096] deviation is the Week 4 Follow-up raw average daily NRS.  
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 15 GDD-TA-T-004 v2013.9 
 

 
 
 
Approval  Date:  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 16 GDD-TA-T-004 v2013.9 
 

 
 
Approval  Date:  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 17 GDD-TA-T-004 v2013.9 
 

 
 
 
 
Approval  Date:  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 18 GDD-TA-T-004 v2013.9 
 Table 2 Summary of IC Medication/T herapy Requirements in the Study 
 Required stable 
duration prior to 
Screening 
(If continuing as 
stable therapy in the study) Period off medication/treatment prior to 
Screening 
 Permissible RescueaTherapy  
  
 
(Only if previously used the medication prior to study entry with no  tolerability issues) 
Oral Elmiron® (pentosan polysulfate) ≥ 6 months ≥ 4 weeks Prohibited 
Narcotic Analgesics ≥ 8 weeks (at a dose 
no greater than 120 mg morphine 
equivalent per day) ≥ 4 weeks Permitted 
eg, tramadol, hydrocodone, oxycodone, 
fentanyl 
All other oral medications used for the treatment of symptoms of IC such as: 
• Non-narcotic analgesics  
• Tricyclic antidepressants 
• Other antidepressants  
• Anticonvulsants and drugs for 
neuropathic pain   
• Antihistamines  
• Anticholinergics  
• Medications for LUTS ≥ 8 weeks ≥ 4weeks Permitted - Any oral pain relieving 
medications used to treat IC, such as: 
• analgesics (eg, acetaminophen) 
• tricyclic and other antidepressants 
(eg, amitriptyline) 
• anticonvulsants and drugs for neuropathic 
pain (eg, gabapentin) 
 
Prohibited –  
• treatments for LUTS eg, anticholinergics 
• IV lidocaine 
Bladder Instillation Therapy N/A Last instillation 4 weeks prior to Screening  Prohibited 
Bladder Hydrodistention (or any procedure 
that may result in bladder distention) N/A Last treatment 6 weeks prior to Screening 
(or until no further beneficial effect is noted if greater than 6 weeks)  Prohibited 
Botulinum toxin therapy (of any serotype) 
for any genitourinary condition N/A ≥ 6 months Prohibited 
Physical Therapy ≥ 8 weeks ≥ 2 weeks N/A 
Fulguration N/A ≥ 4 weeks Prohibited 
IC = interstitial cystitis; IV = in travenous; LUTS = lower urinary tract symptoms; N/A = not applicable 
a Use of rescue medications should be minimized  in the study and avoided if possible.  Th ey may be used on an as needed, short-term basis according to local site practice for 
patients who have an acute exacerbation of pain (“flare”).  All use (dose and time of use) of rescue medication should be recor ded in the pain diary. 
 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 19 GDD-TA-T-004 v2013.9 
 1. Background and Clinical Rationale  
Interstitial cystitis (IC)/bladder pain syndrom e (BPS) is a chronic and debilitating urological 
complex of disorders characterized by [CONTACT_742624], urinary frequency and 
urgency.  The underlying disease process is poorly understood, however, there are 2 
distinguishable and agreed upon phenotypes:  the classic form of IC with Hunner’s Lesions 
(HL) (type 3C) and non-lesion IC/BPS ( Fall et al, 2014 ; Logadottir et al, 2014 ). 
IC with HLs was originally described in 1887 as an inflammatory condition of the bladder, as 
the availability of cystoscopi[INVESTIGATOR_742600] ( Nordling et al, 2012).  The 
European Society for the Study of IC (ESSIC) provides the following description of these 
lesions:  “The Hunner’s lesion typi[INVESTIGATOR_742601] a singular or multiple form as a 
circumscript, reddened mucosal area with small vessels radiating towards a central scar, with 
a fibrin deposit of coagulum attached to this area.  This site ruptures with increasing bladder distension, with petechial oozing of blood fr om the lesion and the mucosal margins in a 
waterfall manner.  A rather typi[INVESTIGATOR_742602]-distension with varying peripheral 
extension” ( Nordling et al, 2012 ; Logadottir et al, 2012; Killinger et al, 2012 ). 
The disease prevalence of IC/BPS varies widely due to lack of global epi[INVESTIGATOR_742603]/BPS.  This is due to the 
fact that the identification of patients was primarily developed to track the course of the 
condition and not by [CONTACT_742625]/BPS patients via patient-reported symp toms which is the 
current recommendation (Berry et al, 2010).  Based on patient self -reported studies of the 
prevalence of IC/BPS in the [LOCATION_002] (U S), there are approximately 83,000 men and 
1.2 million women with IC/BPS across the US ( Hanno et al, 2014 ).  In symptoms-based 
studies evaluating the prevalence of IC/BPS in  the US, across multiple definitions, symptoms 
of IC/BPS were typi[INVESTIGATOR_897] 2 to 3 times more common in women as in men, in which the prevalence was estimated to be approximately 3.3 to 7.9 million women, age 18 or older.  
Only 9.7% of these women reported having been given an IC/BPS diagnosis which suggests 
that IC/BPS may be underdiagnosed ( Berry et al, 2011 ; Suskind et al, 2013).  The 
confounding and overlappi[INVESTIGATOR_742604]/BPS seem to be chronic pelvic pain syndrom e in women and chronic prostatitis in males 
(Berry et al, 2011 ; Suskind et al, 2013). 
With regards to the prevalence of the phenotype of IC with HL, the ESSIC ( van de Merwe et 
al, 2008) and the International Painfu l Bladder Foundation (IPBF) ( Meijlink, 2014) describes 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 20 GDD-TA-T-004 v2013.9 
 IC with HL in the range of 10% to50% of the BPS patient’s population.  IC with HL patients 
are underdiagnosed due to confounding factors such as: 
• confusion caused by [CONTACT_742626]'s ulcer  while it is not an ulcer:  the term 
Hunner's ulcer suggests that it can alwa ys been seen at cystoscopy without 
hydrodistention 
• false impression that HL are rare 
• even when cystoscopy with hydrodistention is performed, HL are likely to be detected 
mainly by [CONTACT_742627].  Biopsy ma y be necessary to prove that it is a HL 
and/or to exclude a carcinoma in situ 
Current guidelines from the American Urologi cal Association (AUA) and ESSIC state that 
the most effective treatments for IC with HL are fulguration by [CONTACT_742628], 
lasercoagulation (burning out and sealing the le sion), or resection (surgical removal of the 
lesion) ( Hanno et al, 2014; Meijlink, 2014 ).  These treatments seem to be most effective, 
improving dramatically symptoms caused by [CONTACT_742629].  Unfortunately, the lesions tend to recur 
with this chronic condition and these treatments need to be administered accordingly between 
several months up to 5 years depending on the individual patients.  These treatments are 
considered extremely invasive and painful pro cedures, they require general anesthesia and 
might introduce surgical complications.  In a ddition, with repeated treatments, they may 
compromise the functionality of the bladder wi th accumulating fibrotic tissue from repeated 
fulgurations or repeated resections.  Current  oral treatments targeting symptomatic relief 
utilized both in IC/BPS and IC with HL are generally unsatisfactory, showing limited efficacy compared with placebo and introduces a systemic side-effects profile ( Chancellor 
and Yoshimura, 2004). 
1.1 Study Rationale 
A major challenge in the treatment of IC with HL  is to deliver effective therapeutic agents to 
ameliorate bladder symptoms and to intervene in the course of the disease, while minimizing adverse effects in a less invasive and compromising manner. 
Lidocaine is a common local anesthetic used in many pain indications across different 
therapeutic areas.  In IC/BPS lidocaine is used for pain treatment as a single agent or in 
combination with other agents (such as s odium bicarbonate or heparin) via bladder 
instillation aimed as a multi-modal treatments.  It  is also used as a rescue treatment for the 
relief of severe pain in a flare ( Meijlink, 2014 ). 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 21 GDD-TA-T-004 v2013.9 
 In addition to lidocaine’s well established effects on nociception, studies suggest local 
anesthetics, including lidocaine, may also sec ondarily suppress inflammation and associated 
hyperalgesia ( Cassuto et al, 2006).  In chronic inflammatory conditions such as asthma, 
lidocaine and lidocaine deriva tive (non-anesthetic lidocaine analog JMF2-1) exhibit anti-
inflammatory properties.  Some animal models suggest that lidocaine inhibits respi[INVESTIGATOR_742605] T-cell pr oliferation and survival through enhancement 
of intracellular cAMP levels ( Olsen et al, 2012 ; Olsen et al, 2011;  Nakahara et al, 2001 ).  
Other animal models suggest that lidocaine pote ntiates the relaxant ef fect of agents that 
activate adenylyl cyclase in bovi ne tracheal smooth muscle due to blockade of muscarinic 
M2 receptor-mediated signal transduction.  It is  likely that lidocaine exerts a synergistic 
effect on the responses to agents that activ ate adenylyl cyclase in bronchoconstriction 
associated with the enhanced parasympathetic nerve activity ( Yunoki et al, 2003 ). 
Studies of lidocaine intravesical instillation in the bladder of IC/B PS patients and healthy 
subjects have consistently reported that intravesical administration of lidocaine at exposures 
up to 800 mg, for durations ranging from 15 minu tes to 2 hours, is safe and well tolerated 
(Birch and Miller, 1994 ; Henry et al, 2001 ; Parsons, 2005;  Nickel et al, 2008;  Higson et al, 
1979;  Yokoyama et al, 1997 ; Yokoyama et al, 2000).  Preliminary pharmacokinetic data from 
these studies also indicate a relatively small fraction of the dose administered intravesically is absorbed systemically.  In one study, for ex ample, peak lidocaine serum levels observed 
following daily intravesi cal instillations of 5mg/kg (~ 350 mg ) of lidocaine for 2 days in IC 
patients averaged 1.3 µg/mL (range:  0.2 to 2.0) ( Henry et al, 2001 ).  This exposure is below 
that commonly achieved following intravenous  (IV) lidocaine administration for the 
management of cardiac ventricular arrhythmias a nd is well below systemic levels associated 
with lidocaine toxicity (> 5.0 µg/mL; Lidoderm
® Prescribing Information, 2013). 
1.[ADDRESS_1015097] (IP), LiRIS®, is a passive nonresorbable Lidocaine-releasing 
intravesical system (LiRIS) whose primary mode of action is the controlled release of 
lidocaine into the bladder over a 14-day period.   
 
 
 
 
 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 22 GDD-TA-T-004 v2013.9 
 1.3 Nonclinical Studies 
A series of Good Laboratory Practice (GLP)-compliant repeat-dose t oxicity studies have 
been conducted in female mixed-breed hounds to assess the safety of TARIS Placebo 
platform (empty device constituent) and LiRIS (100 mg, 200 mg, 400 mg, and 650 mg).  
Across all studies the system was shown to be  well tolerated with no evidence of local or 
systemic effects, no systemic toxicity and no impact on urodynamics. 
1.[ADDRESS_1015098]  been conducted in humans including healthy 
female adults, IC/BPS and IC with HL female patients to assess the safety and efficacy of 
TARIS Placebo and LiRIS ( 200 mg, 400 mg, and 650 mg). 
The TARIS Placebo system was tested in a phase 1, single-blind, randomized, placebo-
controlled (via sham procedure), parallel gr oup study (Study TAR-100-101), to evaluate the 
positional stability and patient tolerance of the system within the bladder over 14 days, evaluating design implications of the insertion and removal procedures.  A total of 10 healthy female volunteers were enrolled in the study; 7 patients underwent insertion and retrieval of 
the TARIS Placebo system and 3 patients had the sham procedure (cystoscopy only).  The 
results of this study showed that the TARIS Placebo system was generally well tolerated in 
healthy female volunteers as adverse events such as haematuria, dysur ia, urethral pain, and 
abdominal pain were similar to thos e seen with the sham procedure. 
The LiRIS 400 mg was tested in a phase 2a  multicenter, randomized, double-blinded, 
placebo-controlled study (Study TAR-100-201) to evaluate safety, tolerability, and efficacy in female patients with IC/BPS in North America.  The study compared LiRIS 400 mg to LiRIS 
Placebo over a 14-day treatment period and 4-week  follow-up period.  Data collected from 
the 104 enrolled patients showed  trends of improvement with LiRIS 400 mg in sub-
populations of IC/BPS patients with high bladder pa in at baseline (7 or greater on 0 to 10 cm 
visual analogue scale [V AS]) and in patients 40 y ears of age or older at time of enrollment.  
Overall, adverse events seen in 10% or more of  enrolled patients were bladder pain, dysuria, 
haematuria, and urinary tract infections (UTIs).  The majority of adverse events were mild or 
moderate in intensity.  There was no meaningful  difference in the incidence of these events 
between the LiRIS 400 mg and LiRIS Placebo groups. 
A phase 1b pi[INVESTIGATOR_742606], tolerability and preliminary efficacy, multicenter, open-label, 
ascending dose study (Study TAR-100-103) of  LiRIS was conducted in a mixed female 
patient population with IC/BPS and IC with HL.  The study enrolled 16 patients in 2 cohorts 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 23 GDD-TA-T-004 v2013.9 
 with 7 patients diagnosed with IC with HL and the remaining the 9 patients with IC/BPS.  
Cohort 1 (200 mg) enrolled 9 patients, and 8 pa tients completed.  Cohort 2 (650 mg) enrolled 
9 patients and all 9 patients completed.  All enrolled patients had LiRIS inserted and indwelling in the bladder for up to a 14-day pe riod and were followed for safety assessments 
for 14 days after removal of LiRIS.  Cohort 2 (650 mg) patients also had additional long-term 
safety and efficacy assessments at [ADDRESS_1015099] common adverse 
events (> 20 % overall) being dysuria, haematuria, and bladder pain.  The majority of adverse events observed were mild or moderate in intensity.  One serious adverse event of “suicidal 
ideations” was reported and deemed to be unrelat ed to LiRIS or the cystoscopy procedure.  
LiRIS 650 mg resulted in higher plasma concen trations and greater amount of lidocaine and 
2,6-xylidine recovered in urin e compared with LiRIS 200 mg.  However, these plasma 
concentrations of lidocaine after LiRIS inserti on were much lower than those associated with 
toxicity (> 5.0 µg/mL).  2,6-xylidine con centrations were on average < 10% of the observed 
plasma concentrations of lidocaine.  Overall, both LiRIS 200 mg and LiRIS 650 mg appear to be safe, tolerable, and efficacious in the tr eatment of bladder pain and irritative voiding 
symptoms.  A subanalysis of the IC with HL patients, showed improvement in inflammatory 
findings with 6 out of the 7 patients enrolled wi th pre-existing HLs, revealing a resolution of 
lesions at the time of LiRIS removal.  This inte resting finding might be attributed to the anti-
inflammatory properties of li docaine described earlier. 
Based on the results from the TAR-100-103 stu dy that showed resolution of lesions, a 
phase 1b open-label study of LiRIS 400 mg in female IC patients with HL (Study TAR-100-105) was initiated.  In this study, pati ents were treated with 2 consecutive LiRIS 
400 mg each, to support the evaluation of lesions resolution compared to baseline as a response to an accumulative dose of 800 mg of lidocaine released continuously over a period 
of 28 days.  This is based on the assumption that the anti-inflammatory mechanism of action would require a higher dose over a longer treatment period to show further improvement in 
lesion resolution compared to results shown in the TAR-100- 103 study, with no additional 
risk to the patients.  The study has completed en rollment (N = 10) at [ADDRESS_1015100] 2014. 
The purposes of this study is to develop a bett er understanding IC with HL and the potential 
of the LiRIS 400 mg as a therapeutic agent in both symptoms relief and intervening in the 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015101] an accepta ble safety profile and is more efficacious 
than placebo for the treatment and correspond ing symptoms of IC with HL in female 
patients. 
3. Study Design 
This study is a multicenter, randomized, double-b lind, placebo-controlled, study to evaluate 
the safety and efficacy of the LiRIS 400 mg in female patients with IC with HL.  This study 
includes up to 2 treatments.  To receive Treatment  1, patients will be randomized in a 2:1:1 
ratio to 1 of 3 treatment groups receiving over a 28-day treatment period either: 
Group 1:  2 consecutive LiRIS 400 mg (N = 38)  
Group 2:  2 consecutive LiRIS Placebo (N = 19) 
Group 3:  LiRIS Placebo followed by [CONTACT_742630] 400 mg (N = 19)  
Patients who qualify for Treatment 2, will r eceive LiRIS 400 mg over a 14-day treatment 
period followed by 4 weeks of observation until exit.  Patients will be stratified based on 
screening baseline pain score ( ≤ 5 or > 5). 
For patients who participate in the study and receive only Treatment 1, the duration will be 
[ADDRESS_1015102] IP removal.   For patients who qualify and receive 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 25 GDD-TA-T-004 v2013.9 
 Treatment 2 (active LiRIS only), the minimum duration of participation is 16 weeks (if 
qualification and Treatment [ADDRESS_1015103] removal of 
Treatment 1 IP) and the  maximum durati on of study participation is 36 weeks (if 
qualification and Treatment [ADDRESS_1015104] removal 
of Treatment 1 IP). 
The study IP will be inserted in to the bladder using a rigid cystoscope and removed using 
graspi[INVESTIGATOR_742607] a rigid or flexible cystoscope. Patient-reported pain via the Numeric Rating Scale (NRS), and pain medication use will be 
recorded on a daily basis throughout the duration of the study on an electronic diary.  Patient 
reported voiding frequency and urgency, includ ing pre- and post-voidi ng pain will be 
recorded on a paper bladder diary.   
 
 
  
4. Study Population and Entry Criteria 
4.1 Number of Patients 
Approximately 76 patients will be enrolled at ap proximately 25 sites in the US and Canada to 
achieve 72 evaluable patients (N = 36, N = 18, and N = 18 in the 3 treatment groups, 
respectively) based on an anticipated dropout rate of 5%.   
4.[ADDRESS_1015105] of  adult female patients with a history of IC with HL along 
with the associated symptoms as previously reported in guidelines by [CONTACT_742631] 
(2008). 
4.3 Inclusion Criteria 
The following are requirements for entry into the study: 
 
 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 26 GDD-TA-T-004 v2013.9 
  
 
 
5. A 
diagnosis of IC with HL defined as: 
• an unpleasant sensation (pain, pr essure, discomfort) perceived to be related to the urinary 
bladder, associated with lower urinary tract symptoms (LUTS) of more than 6 months 
duration in the absence of infection or other identifiable causes (van de Merwe et al, 
2008), documented history or patient reported 
and  
• documented history of an observation of HL via cystoscopic procedure in which a 
lesion is defined as a circumscript, reddene d mucosal area that can be small vessels 
radiating towards a central scar, and/or a fibrin deposit of coagulum attached to 
this area.  Lesions may also be linea r, fissure-like, and may be bleeding. 
 
 
  
 
  
  
 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 27 GDD-TA-T-004 v2013.9 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4 Exclusion Criteria 
The following are criteria for exclusi on from participating in the study: 
1. Patient who is pregnant, nur sing, or planning a pregnanc y during study participation 
2. Patient of childbearing potential who is unable or unwilling to use a reliable form of 
contraception during the study (as defined in Section [IP_ADDRESS])  
 
 
 
 
  
 
 
  
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 28 GDD-TA-T-004 v2013.9 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
  
  
  
  
  
 
 
 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 29 GDD-TA-T-004 v2013.9 
  
 
 
 
  
 
 
 
 
 
 
 
 
19. Previous exposure 
to LiRIS in a TARIS c linical study within 6 months prior to 
Screening. 
 
 
 
 
 
4.5 Permissible and Prohibited Medications/Treatments 
4.5.1 Permissible Medications/Treatments 
Therapy considered necessary for the patient’s welfare may be given at the discretion of the 
investigator.  Patient should be instructed to maintain a stable dose of chronic medications 
during the study whenever possible.  Please see Ta ble [ADDRESS_1015106] of permissible medications 
with the required stable duration prior to Scre ening (if continuing as stable therapy in the 
study), the period off medication/ treatment prior to Screening, and permissible short-term 
rescue therapy (medication must have been us ed previously, prior to  study entry with no 
tolerability issues).  See Section 4.5.3 regarding rescue medication. 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015107] therap ies, and concurrent procedur es should be recorded on the 
appropriate electronic case re port form (eCRF).  If the pe rmissibility of a specific 
medication/treatment is in question, please contact [CONTACT_742632]. 
[IP_ADDRESS]  Definition of Females of (Non )Childbearing Potential and/or 
Acceptable Contraceptive Methods 
For purposes of this study, females will be considered of childbearing potential unless they are naturally postmenopausal or  permanently sterilized (ie,  hysterectomy).  Natural 
menopause is defined as the permanent ce ssation of menstrual periods, determined 
retrospectively after a woman has experienced 12 months of  amenorrhea without any other 
obvious pathological or physiological cause.  Fo r women of childbearing potential who may 
participate in the study, the following met hods of contraception, if properly used, are 
generally considered reliable:  hormonal contraceptives (ie, or al, patch, injection, implant), 
male condom with intravaginal spermicide, diaphragm or cervical cap with spermicide, 
vaginal contraceptive ring, intraute rine device, surgical sterili zation (bilateral tubal ligation, 
bilateral salpi[INVESTIGATOR_1656]), vasectomized partner, or  total sexual abstinence (when this is in line 
with the preferred or usual lifestyle of the patient). 
The investigator and each patient  will determine the appropriate method of contraception for 
the patient during the participation in the study. If a female becomes pregnant during the study, the investigator will notify Allergan 
immediately after the pregnancy is confirmed and the patient will be exited from the study 
after appropriate safety follow-up.  The investigator will (1) notify the patient’s physician 
that the patient was being treated with an investigational drug LiRIS 400 mg or LiRIS 
Placebo, and (2) follow the progress of the preg nancy.  The investigator must document the 
outcome of the pregnancy and provide a copy of the documentation to the Medical Safety 
Physician assigned to this study. 
4.5.2 Prohibited Medications/Treatments 
Use of the following medications/treatments is  prohibited throughout study participation: 
• botulinum toxin treatment of any sero type for any genitourinary indication 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 31 GDD-TA-T-004 v2013.9 
 • patients who are not on a stab le dose of any oral medica tions/physical therapy (see 
Table 2) for the treatment of IC should not use them for the duration of the study 
unless they are being used as a rescue medication (Section 4.5.3) 
Note:   Possible effects on study safety a nd endpoints should be taken into 
consideration when initiating treatment during the trial with any of the oral 
medications listed in Table 2 for an indication outside of IC.   
• any intravesical pharmacotherapi[INVESTIGATOR_014] (eg,  dimethyl sulfoxide [DMSO], sodium 
hyaluronate [Cystistat®], chondroitin [Uracyst®], pentosan polysulfate sodium 
[Elmiron®], heparin, lidocaine, sodium bicarbona te, capsaicin or resiniferatoxin) 
• use of electrical stimulation or neuromodula tion devices (implanted and external) for 
the treatment of LUTS or pain.  If a patie nt is enrolled into the study with a device 
still implanted, it must be inactive for 4 weeks prior to treatment on Randomization/Day [ADDRESS_1015108] remain inactive for the duration of the study 
• hydrodistention (or any other procedure that  may result in bladder distention) 
• general or spi[INVESTIGATOR_742608]/removal 
• products other than IP that would result in systemic lidocaine exposure (eg, lidocaine 
patch [Lidoderm], IV lidocaine, intrathecal lidocaine) 
The decision to administer a prohibited medicat ion/treatment is done with the safety of the 
study participant as the primary consideration.  When possible, the assigned Medical Safety 
Physician for this study should be notified before the prohib ited medication/treatment is 
administered. 
4.5.[ADDRESS_1015109] an acu te exacerbation of pain (“flare”) (Table 2).  
The following medications may be used: 
• any oral pain relieving medication (except herbal medications) that the patient has 
previously used for IC within the 3 months prior to Screening and has been tolerated  
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 32 GDD-TA-T-004 v2013.9 
 Use of any nonpain relieving medications (eg, anticholinergics) is prohibited as rescue 
medication. 
All usage of rescue medication should be record ed (time of use and dose) on the pain diary 
by [CONTACT_742633].  In addition sites should question 
patients at all visits regarding the use of re scue medications between visits and any such 
usage should be recorded in the appropriate eCRF. 
4.5.[ADDRESS_1015110] be recorded on the concomitant medications eCRF. 
4.5.5 Study Treatment Anesthesia 
Study treatment administration and removal ma y be performed using local anesthesia 
(general or spi[INVESTIGATOR_742609]) and/or  sedation.  The type of anesthesia used is at 
the investigator’s discretion, depending on the patient’s expected tolerability and available 
facilities.   
One or more of the following options are permitted as per local site practice: 
• local anesthesia or lubricating gel to the urethra to facilitate cystoscope insertion 
• sedatives (oral or IV) may be administered 
All anesthesia should be reco rded on the appropriate eCRF.  
4.5.[ADDRESS_1015111] ed (vegan, vegetarian, 
non-vegetarian). 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 33 GDD-TA-T-004 v2013.9 
 5. Study Treatments 
5.1 Study Treatments and Formulations 
The study treatment is LiRIS 400 mg (AGN-201025). 
LiRIS is a passive nonresorbable lidocaine-releasing intraves ical system whose primary 
mode of action is the controlled release of lidoc aine into the bladder ov er a 2-week period.  
The device constituent of LiRIS (both active and placebo) is constructed of medical grade 
silicone (elastomer) and nitinol wire, which provides the bladder-retentive property of the 
system. 
 
  
 
 
 
 
 
 
5.[ADDRESS_1015112] of the lidocaine. 
5.3 Methods for Masking/Blinding 
All study treatments (active and placebo) and pack aging will be identical in order to maintain 
masking of the study.  The study treatment will be  identified as an investigational compound.  
The study number and kit number will be identified on the unit label. 
5.4 Treatment Allocation Ratio and Stratification  
Patients will be randomized centrally and stra tified on Randomization/Day 0 by [CONTACT_742634] ( ≤ 5 or > 5).  Each patient within a stratification group will be randomized using an 
automated randomization system to 1 of 3 treatment groups (LiRIS 400 mg/LiRIS 400 mg; 
LiRIS Placebo/LiRIS Placebo; LiRIS Pl acebo/LiRIS 400 mg) in a 2:1:1 ratio. 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 34 GDD-TA-T-004 v2013.9 
 5.5 Method for Assignment to Treatment Groups/Randomization 
Following the Screening period, patients who m eet the study inclusion/exclusion criteria and 
day of treatment criteria will be assigned a randomization number through the interactive 
voice response system (IVRS)/ interactive we b response system (IWRS) which determines 
the treatment group assignment.  Study medication will be labeled with medication kit numbers.  The IVRS/IWRS system will provide the site with the specific medication kit 
number(s) for the patient that corresponds to the treatment group to which the patient was assigned.  The site will also use IVRS/IWRS to assign a new kit number to each patient who 
meets Treatment 2 criteria. 
5.6 Treatment Regimen and Dosing 
5.6.1 Treatment 1  
Eligible patients will be randomized on Randomization/Day 0 to receive Treatment 1, LiRIS 400 mg/LiRIS 400 mg; LiRIS Placebo/Li RIS Placebo or LiRIS Placebo/LiRIS 400 mg 
(Section 5.4).  Patients will have the Treatment 1, 1
st IP inserted on Randomization/Day [ADDRESS_1015113] IP removal, the 2nd IP 
(LiRIS 400 mg or LiRIS Placebo) will be inse rted and subsequently removed on Day 28.  
Patients will be followed for [ADDRESS_1015114], 
qualify, and receive Treatment 2 IP from Week 4 Follow-up until Week 20 of Treatment 1.  In the event that the Treatment 2 IP cannot be inserted on the day of qualification, Treatment 2 
may be rescheduled within 14 days of qualif ication.  The LiRIS will be inserted on 
Treatment 2/Day 0, and will be removed on Day 14.  Patients will be followed for [ADDRESS_1015115]-removal and will be exited from the study. 
5.6.3 Premature IP Removal  
The IP will be removed immediately and appr opriate medical therapy should be instituted 
immediately, if any of the following occur: 
• if patient requests removal of the IP for any reason 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 35 GDD-TA-T-004 v2013.9 
 • if patient becomes pregnant 
• haematuria that is considered by [CONTACT_941] i nvestigator to be clinically significant 
• urinary retention that is considered by [CONTACT_11150] 
• allergic reaction (shortness of  breath, generalized edema, etc) to either LiRIS device 
constituent materials (silicone, nitinol), drug (lidocaine or lactose) and/or excipi[INVESTIGATOR_840] 
(povidone, polyethylene glycol)  
• signs of lidocaine toxicity ( Xylocaine® Injection Package Insert, 2010) where 
toxicities associated with lidocaine incl ude but are not limited to light-headedness, 
nervousness, perioral tingling, tingling or numbness of the tongue, confusion, 
dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, 
cold or numbness, twitching, tremors, convulsions, unconsciousness, respi[INVESTIGATOR_41826], respi[INVESTIGATOR_742610], hypotension, and 
cardiovascular collapse, which may lead to cardiac arrest 
• a condition or situation that, in the investigator’s opi[INVESTIGATOR_21677], may put the patient at 
significant risk 
5.7 Storage of Study Medications/Treatments 
The study medication must be stored in a secu re area and administered only to patients 
entered into the clinical study, at no cost to  the patient, in accordance with the conditions 
specified in this protocol. 
IP must be stored at room temperature  and protected from light, 
representing a usual and customary working envir onment.  The IP must not be frozen.  Sites 
must report any temperature excu rsions as described in the St udy Manual or contact [CONTACT_742635]. 
5.8 Treatment Administration  
The insertion, removal, and inspection of the IP are to be completed by [CONTACT_093](s) 
involved with the study.  Detailed instructions for the insertion and removal of the IP are in 
the Study Manual . 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015116] be fulfilled prior to the administration of study 
treatment. 
• confirm that patient did not have a sy mptomatic UTI during the baseline pain 
eligibility criteria assessment period 
• negative urine dipstick reagent st rip test (for leukocyte estera se and/or nitrites) and, in 
the investigator’s opi[INVESTIGATOR_1649], patient is as ymptomatic for a UTI on the day of study 
treatment 
• negative urine pregnancy result (for patient s that are of child bearing potential) 
• investigator continues to deem treatment is  appropriate and no condition or situation 
exists which, in the investigator’s opi[INVESTIGATOR_21677], puts the patient at significant risk from 
receiving treatment 
5.8.[ADDRESS_1015117] retreatment (Treatment 2) at any time from the Week 4 Follow-up clinic visit up through the Week 20 Follow-up clinic visit.  A patient will be eligible to receive 
Treatment 2 (LiRIS 400 mg) only if all of the following criteria are met: 
• completed Treatment 1 schedule of visits and procedures from the Week 4 Follow-up 
visit through qualifica tion, in the opi[INVESTIGATOR_871] 
• negative urine dipstick reagent st rip test (for leukocyte estera se and/or nitrites) and, in 
the investigator’s opi[INVESTIGATOR_1649], patient is as ymptomatic for a UTI on the day of study 
treatment 
• negative urine pregnancy result (for patient s that are child bearing potential) and are 
willing to continue using acceptable method of contraception 
• Investigator continues to deem treatment is  appropriate and no condition or situation 
exists which, in the investigator’s opi[INVESTIGATOR_21677], puts the patient at significant risk from 
receiving treatment 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 37 GDD-TA-T-004 v2013.9 
 6. Response Measures and Summary  of Data Collection Methods 
6.1 Efficacy Measures 
6.1.1 Primary Efficacy Measure 
• average daily bladder pain score patient e xperienced over the previous 24-hour period 
as measured by [CONTACT_742636] 0 to 10, recorded on a 7-day pain assessment tool.   
The primary timepoint is Week 4 following Treatment 1 2nd IP removal. 
6.1.2 Secondary Efficacy Measures 
• number of HLs assessed by [CONTACT_978] [INVESTIGATOR_742611] 
• composite score of HL calculated based on num ber, size, and severity of the lesions 
6.1.3 Other Efficacy Measures 
  
 
  
 
  
 
  
 
  
 
    
6.1.4 Health Outcomes Measures 
•  
 
  

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 38 GDD-TA-T-004 v2013.9 
 •   
6.2 Pharmacokinetics Measures  
 
 
 
  
  
6.3 Safety Measures 
• adverse events and serious adverse events  
• physical examination 
• vital signs 
• any abnormal cystoscopy findings at insertion and removal 
• pregnancy testing for women of childbearing potential 
• urine dipstick reagent test 
• urine analysis (with urine culture and sensitivity, as applicable) 
• urine cytology (at Screening only) 
• post-void residual (PVR) urine volume measurement 
• hematology and non-fasting serum chemistry 
• concomitant medications 
• concurrent procedures 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015118] Events 
• voiding of the IP  
• damage to the IP during insertion or removal procedures 
• damage to the IP that is not related to insertion or removal procedures 
6.5 Examination Procedures, Tests,  Equipment, and Techniques  
Screening procedures can commence once the informed consent and data 
authorization/protection form have been obtaine d.  Screening will be considered to have 
started (eg, Day -28) at the time of the first Screening activity or procedure.  On completion 
of Screening, when all the required inclusion/ex clusion have been met, the patient will be 
randomized and be considered enrolled into the study. 
Evaluations should be performed by [CONTACT_742637].  If it is not possible to use the same  evaluator to follow the patient, then it is 
preferable to have the evaluati ons overlap (examine the patient together and discuss findings 
for at least one visit). 
6.5.1 Medical History/Demographics 
A complete medical history will be obtained and is to include diagnosis or symptom, date of 
onset, current status, associated surgical pro cedures, detailed genitourinary history, prior 
medications/treatments, and reasons for discontin uation.  In addition key demographics (ie, 
information about patients dietary lifestyle [vegan, vegetarian, non-vegetarian], smoker 
versus non-smoker) will be documented for each patient. 
6.5.2 Physical Examination 
The physician or appropriately qualified designee will perform a complete physical 
examination (PE) and examine the patient for any physical abnormalities of the following 
body systems:  head, ears, eyes, nose, and throat (HEENT) and neck, cardiovascular, 
respi[INVESTIGATOR_696], abdomen, musculoskeletal, and skin systems will be performed at the appropriate 
scheduled visits (see Table 1). 
An abbreviated PE includes cardiovascular, respi[INVESTIGATOR_696], and abdomen examination.  Please 
refer to Table 1 for the scheduled visit in which the abbreviated PE should be performed 
compared with a complete PE. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015119].  The initial examination should comprise visual 
inspection of the external genitalia for signs of  infection, tumors, or  urethral caruncle, a 
superficial tactile examination of the extern al genitalia to elicit superficial non-bladder 
related tenderness and a careful, gentle palpation of the vulva l fourchette and levator ani 
muscles to assess pelvic floor pain etiology and to rule out high muscle-tone pelvic floor 
dysfunction as the primary source of the patient’s pain.  Finally the posterior urethra, bladder 
neck, and bladder should be palpated to elicit bl adder-related pain.  This examination must be 
included as a part of the Screening period PE. 
6.5.4 Vital Signs, Weight and Height Measurements 
Vital signs will be measured prior to any invasive procedures as outlined below: 
• pulse rate (beats per minute) :  patients should be res ting in a seat ed position 
• blood pressure (mm Hg):  patients should be resting in a seated position.  
Systolic/diastolic blood pressure is th en measured with a sphygmomanometer. 
• temperature (oF or oC):  patients should be seated and the body temperature taken 
according to local site practice 
• body weight (Screening and exit) and height (Screening vis it only) will be measured 
according to local site practice 
6.5.5 Clinical Laboratory Assessments 
All clinical laboratory samples will be analyzed  at a central facility.  For schedule of blood 
and urine samples collection,  please refer to Table 1. 
Analytes will be tested as specified below: 
Hematology:  red blood cells ( RBC); RBC Indices:  mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), 
RBC morphology; white blood cells (WBC); WB C differential (% and absolute):  
neutrophils, lymphocytes, monocytes, eosinophils, basophils, hematocrit; hemoglobin; and platelets 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 41 GDD-TA-T-004 v2013.9 
 Blood Chemistry:  albumin, alkaline phosphatase, alanine aminotransferase (ALT [SGPT]), 
aspartate aminotransferase (AST  [SGOT]), total and direct b ilirubin, blood urea nitrogen 
(BUN), calcium, chloride, creatinine, gamma glutamyltransferase (GGT), globulin, non-
fasting glucose, potassium, to tal protein, and sodium  
Urine Analysis and Urine Culture and Sensitivity:  Urinalysis will be performed at all clinic 
study visits; a urine cu lture and sensitivity test will also be performed when urinalysis results 
are suggestive of a potential UTI (positive leukocyte esterase, nitrites, blood and/or microscopic sediments such as WBCs, RBCs, and/or bacteria). 
Urine analytes to be te sted are listed below: 
Urinalysis:  Color, appearance, specific gravity; pH, protein, gl ucose, ketones, occult blood, 
leukocyte esterase, nitrite, bili rubin, urobilinogen, crystals; microscopic examination if 
positive for protein, leukocyte, o ccult blood, nitrite, or crystals 
Urine Culture and Sensitivity:  Culture, qua ntitation, isolation, identification, and 
susceptibility Urine cytology is performed at the Screening visit only.  Abnormal urine cytology suspi[INVESTIGATOR_742612] a urothelial malignancy should be investigat ed by [CONTACT_742638], and only if such malignancy is ruled out  should the patient be enrolled.  Results of 
the investigation will be reco rded in the source documents. 
Serum and Urine Pregnancy Test:  Beta-human chorionic gonadotropin (β -HCG) performed. 
Pregnancy testing will be conducted for wome n of childbearing potential using serum β -HCG 
test with the exception of any day of IP insertion where urine will be used. 
Urine Dipstick Reagent Strip Tests (Urine Dipstic k): The urine dipstick is used to identify a 
potential UTI and to provide immediate information to the investigator. 
6.5.[ADDRESS_1015120] blood and urine collected for pharmac okinetic analysis of 
lidocaine and 2,6-xylidine (non-smokers only) during both Treatment 1 and Treatment 2 (if 
applicable). 
Plasma samples will be collected and stored at  -20°C or colder until shipped to the central 
laboratory facility.  Detailed instructions for th e collection, processing, storage and shipment 
of samples are provided in the Central Laboratory Manual. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015121]-void Residual  
Bladder PVR is to be assessed per the site’s standard of care method (eg, bladder scan) but 
should be performed preferably immediately after voiding.  The same method should be 
consistently used throughout the study.  Please see Table 1 for the visits at which PVR should 
be assessed.   
6.5.8 Cystoscopic Examination 
All patients will undergo a cystoscopic examination on the days of Insertion of the IP to rule 
out the presence of any bladder or urethra anat omical feature that, in the opi[INVESTIGATOR_1070], might prevent the safe placement, indwelling use, or removal of IP, such as 
bladder fistulae or stone.  In addition, prior to the intial IP in sertion on Day 0, the presence of 
HLs will be confirmed.  If during the cystoscopic exam, the investigator discovers an abnormality that would prevent the safe placement,  indwelling use, or removal of the IP, the 
patient will not receive treatment an d will be withdrawn from the study.  
A brief cystoscopic examination for safety purpo ses will also be conducted on all patients at 
the Treatment 1 and Treatment 2 Day of Removal Visits (see Table 1). 
During each cystoscopy, the investigator will count the number of lesions visible while 
performing the bladder scan for bladder mappi[INVESTIGATOR_007]. Investigators may recommend that the patient ta ke pain medication up to 6 hours prior to the 
cystoscopic procedure and continuing for 24 hours after the procedure to minimize patient 
anxiety and discomfort. 
6.5.9 Bladder Mappi[INVESTIGATOR_742613], a standardized  video capture protocol for bladder mappi[INVESTIGATOR_742614], size, and severity of lesions 
during the study as a result of treatment.  
6.5.10  Insertion and Removal of IP 
For instructions on insertion and rem oval of IP, please see the Study Manual. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015122]-use Assessment 
Immediately after removal of the IP, the inve stigator will take 2 photographs of the IP 
(wireform side up and wireform side down), and will perform a visual inspection of the IP to 
confirm that it was removed from the patient in  its entirety and none of the IP components 
(nitinol wire, silicone) are missing.  The investigator wi ll document any observations of 
visible damage or changed appearance of IP (e g, wireform protrusion, torn silicone, change 
in color, etc) in the eCRF, and notify Allergan or designee within [ADDRESS_1015123] approp riate testing to confirm that no IP components 
are left indwelling in the patient, such as a pe lvic examination, abdominal x-ray, abdominal 
ultrasound, and/or cystoscopic exam. 
Each IP removed from the bladder of a study pati ent will be retained and sent to Allergan for 
a post-use assessment.  Detailed instructions for the storage and shipment of the IP 
post-removal are provided in the Study Manual. 
6.5.[ADDRESS_1015124] pain scores on an electronic hand held device.  Patient s will be asked to rate their 
daily pain on a pain NRS consisting of an 11- point integer scale ranging from 0 for “no pain” 
to 10 for “worst pain imaginable”.  The pain assessment tool will be provided to patients at 
the Screening visit and patients will be instructed on how to correctly complete the bladder 
pain assessment by [CONTACT_7893].  If the pati ent has a confirmed or suspected UTI, pain data 
should not be collected until the signs and symptoms of the UTI have resolved. 
The pain assessment will continue every day up to and including the day prior to the Exit 
Visit.  Patients should complete the pain asse ssment questions at approximately the same 
time each day on the pain assessment tool (prefera bly at the end of each day, prior to 12:[ADDRESS_1015125] 24-hour period).   
Baseline and Follow-up Visit Pain Assessment 
The baseline pain assessment will be calculated based on at least 5 consecutive days of data 
collected in the 7 days immediately prior to  the Randomization/Day [ADDRESS_1015126] 14 days immediately prior to Randomization/Day 0 in order to acclimate the 
patient to the process of assessing their pain on a daily basis.The primary timepoint for the 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 44 GDD-TA-T-004 v2013.9 
 daily average pain score is at 4 weeks following Treatment 1, 2nd IP removal.  The patient’s 
Pain NRS for this timepoint will be the averag e of the 7-day “average  pain in your bladder 
over the last 24 hours”. 
If the patient’s study visit is rescheduled, the s ite must ensure that adequate time has been 
provided for the patient to record at least [ADDRESS_1015127] udy to capture micturition parameters.  Prior to 
receiving the diary, patients will be instructed and trained on the use of the diary, the data to 
be collected and instructed on how  to correctly complete the bladder diary by [CONTACT_7893]. 
Patients should enter data into the bladder diary following each void (day and night) for 
3 consecutive days immediately prior to th e designated clinic visit (see Table 1). 
The 3-day bladder diary will capture the numbe r of day-time voids and the number of night-
time voids (where night time is defined as the time the patient goes to bed until the time the 
patient gets out of bed the next morning) over a period of [ADDRESS_1015128] of 
pain that will be evaluated at the Screening visit for study eligibility.  Items are rated on a 
scale from 0 to 4 and the PCS has 3 differen t categories:  Rumination, Magnification, and 
Helplessness.  It is hypothesized that pain catastrophizing is related to various levels of pain, 
physical disability, and psychological disability in clinic al and nonclinic al populations. 
  
 
 
 
 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 45 GDD-TA-T-004 v2013.9 
  
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
6.5.18  Concomitant Medications and Concurrent Procedures 
Patients will be instructed to capture all pain  medication (stable dose and rescue medications) 
taken for IC pain during the study on the electr onic diary which will capture what medication 
was taken and when (date and time).  Site staff will review the pain medication electronic 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015129] arting at the time of Screening and ending at 
the patient Exit Visit (either at completion of follow-up to Treatment 1 or Treatment 2, as 
applicable).   
All concomitant medications and concurrent proc edures must be recorded in the eCRF with 
all specific details associated with ea ch use of the medication/procedure. 
6.5.19  Adverse Events  
Details regarding the definitions, documentation,  and reporting of  a dverse events/serious 
adverse events are in Section 9. 
6.5.20  IP Events 
An IP event includes any observation of the IP  not performing as intended.  Examples of IP 
Events are: 
• voiding of the IP  
• damage to the IP during insertion or removal procedures 
• damage to the IP that is not related to insertion or removal procedures 
An IP Event could occur any time between when the IP is removed from the packaging 
through the insertion/rem oval procedures and the return of the IP.  
Each IP Event will be assessed by [CONTACT_742639], and any adverse events identified will be managed according to details in 
Section 9. 
All IP Events, in the opi[INVESTIGATOR_144457], should be repor ted to Allergan or designated 
representative. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 47 GDD-TA-T-004 v2013.9 
 6.6 Other Study Supplies 
The following will be provided by [CONTACT_78562]: 
  
  
 
 
  
   
 
  
  
  
  
  
  
  
  
  
 
  
6.[ADDRESS_1015130]-void pain scores will be reported by 
[CONTACT_221816] a paper bladder diary.   
  All clinical study data will be entered in to an electronic data 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 48 GDD-TA-T-004 v2013.9 
 capture (EDC) system via eCRFs.  Source documents  will be used and stored at the sites, and 
may include a patient’s medical records, hospi[INVESTIGATOR_1332], clinical charts, patient chart, copy of 
the EDC file, as well as the results of diagnostic tests (if performed). 
7. Statistical Procedures 
All statistical analyses will be detailed in the st udy statistical analysis plan (SAP), which will 
be finalized prior to database lock.  This doc ument will provide a more technical and detailed 
description of the proposed data analysis met hods and procedures.  Two analyses are planned 
for this study, including the pr imary analysis and the final analysis.  The primary analysis 
will be conducted at the time when the last patient completes the primary timepoint that is 
Week 4 following Treatment 1 2nd IP removal.  The final analysis will be conducted when all 
patients complete or exit the study. 
7.1 Analysis Populations 
The modified intent-to-treat (mITT) analysis  population:  The mITT population will include 
all patients who were randomized and received at leas t 1 IP insertion in Treatment 1.  The 
efficacy data will be analyzed as ra ndomized using the mITT population. 
Safety analysis population:  The safety populatio n will include all patient s enrolled in this 
study and received at least one IP.  The safety data  will be analyzed as treated using the safety 
population. 
Pharmacokinetic evaluable  population:  Th e pharmacokinetic population will include all 
patients enrolled in this study and who have at  least one plasma or urine pharmacokinetic 
concentration measurement post-IP insertion and for whom the IP is successfully removed. 
Per-protocol (PP) analysis population:  The PP  population will include all patients who retain 
the [ADDRESS_1015131] removal of the 2nd IP of Treatment 1 w ithout any significant 
protocol deviations.  Protocol deviations will be determined prior to database lock. 
7.2 Collection and Derivation of Pr imary, Secondary, and Other 
Efficacy Assessments 
Average daily bladder pain NRS:  The pain NRS will be used to assess bladder pain over the 
previous 24-hour period.  The pain NRS consists  of an 11-point integer scale ranging from 0 
for “no pain” to 10 for “worst pain imaginable.”  Patients are instructed to complete the pain 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 49 GDD-TA-T-004 v2013.9 
 NRS in an electronic handheld diary by [CONTACT_742640]: 
Please describe the average pain in your bladder over the last 24 hours. 
The patient’s baseline pain NRS will be the average of the 7-day “average pain in your 
bladder over the last 24 hours” NRS scor es from the 7 reported days prior to 
randomization/1st IP insertion.   
Study baseline for a patient is defined as the last measurement availa ble prior to the first 
treatment. 
Missing Data 
Every effort will be made to obtain required data at each scheduled evaluation from all 
patients who have been enrolled.  Missing data will only be imputed for the analysis of the 
primary efficacy variable. 
7.2.[ADDRESS_1015132] removal of 2nd IP of Treatment 1 as compared to study baseline. 
The average daily pain NRS of the preceding 7 days (at least 5 consecutive days) will be 
calculated and used to calculate ba seline and change from baseline at each scheduled visit.  If 
no data are available for at least a period of [ADDRESS_1015133] of the 2 values that is available (ie, Week 2 or 3 Follow-up).     
7.2.2 Secondary Efficacy Variables 
There are 2 secondary efficacy variables: 
• change from baseline in number of HLs assessed by [CONTACT_978] [INVESTIGATOR_742615], the investigator will count the number of lesions visible 
while preforming the bladder scan for bladder mappi[INVESTIGATOR_007].  
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 50 GDD-TA-T-004 v2013.9 
 • change from baseline in composite score of HL calculated based on number, size, and 
possibly severity of the lesions 
A standardized video capture protocol for bladder mappi[INVESTIGATOR_742616], the size and the severity, of lesions during the 
study as a result of treatment. 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015134] IP removal visit is the same 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 52 GDD-TA-T-004 v2013.9 
 between the LiRIS 400 mg/LiRIS 400 mg gr oup and the LiRIS Placebo/LiRIS Placebo group 
(2 consecutive placebo’s). 
The alternative hypothesis is that the mean chan ge from baseline in average daily bladder 
pain NRS at Week [ADDRESS_1015135] IP removal is different between the 
LiRIS 400 mg/LiRIS 400 mg group and th e LiRIS Placebo/LiRIS Placebo group. 
Methods of Analysis 
All continuous variables will be summarized showing the number, mean, median, standard 
deviation, minimum, and maximum values.  Discrete variables will be summarized showing 
the frequency and percentage of the study population.   As this is a phase 2 trial, there will be 
no p-value adjustment for multiplicity.  Plots of efficacy variables (value and/or change from baseline) will be presented over time. 
7.3.1 Demographics, Baseline Characteristics and Disposition 
Analyses 
Demographic and baseline charac teristic data, including age, race, ethnicity, and abnormal 
PE results will be summarized and presented by [CONTACT_742641] 1 and 
Treatment 2 separately. 
Patient disposition for both Treatment 1 and Treatment 2 will be displayed by [CONTACT_6490].  For those discontinuing the study premat urely, the reason for study termination will 
be recorded and time on study will be calculated. 
7.3.2 Efficacy Analyses 
All efficacy analyses will be performed on the mITT population.  Analyses of the primary efficacy variable will also be performed on the PP population.   
Plots of values and change from baseline or percentage in each variable category, as appropriate, will be presented by [CONTACT_468848]. 
All analyses are based on 2-sided tests w ith significance level of 0.10 unless otherwise 
specified. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 53 GDD-TA-T-004 v2013.9 
 [IP_ADDRESS]  Primary Efficacy Analyses 
The primary endpoint was the change in bladder pain at Week [ADDRESS_1015136] IP 
removal of Treatment 1 as compared to study baseline. 
The average daily pain NRS of the preceding 7 days (at least 5 consecutive days) will be 
calculated and used to calculate change from baseline at each scheduled visit.   Calculation of 
averages will employ available data without imput ation.  If no data are available for a given 
7-day period (at least 5 consecutive days) that  average will be considered missing for that 
patient. 
The change from baseline in average daily bla dder pain score at Week [ADDRESS_1015137] 
IP removal of Treatment 1 will be analyzed using the analysis of covariance (ANCOV A) 
model, using the baseline value as the covariate, and stratific ation factor (baseline bladder 
pain NRS:  ≤  5 or > 5) and treatment as  factors.  If there is no  valid Week [ADDRESS_1015138] of the 2 values that is available (ie, Week 2 or 3 
Follow-up).    
The same ANCOV A analysis will also be perf ormed at all other postbaseline timepoints. 
[IP_ADDRESS]  Secondary Efficacy Analyses  
The analysis of the continuous secondary efficacy variables at Week [ADDRESS_1015139] 
IP removal of Treatment 1 may be analyzed similarly as for the primary efficacy variable of 
average daily bladder pain NRS, as described in Section [IP_ADDRESS] Primary Efficacy Analyses.  
However, no imputation method will be applied. 
  
 
 
 
 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 54 GDD-TA-T-004 v2013.9 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3.3 Safety Analyses 
Safety data will be analyzed using safety population. 
Safety assessments will be reporte d by [CONTACT_742642]: 
• adverse events  
• clinical laboratory results  
• urinalysis  
• urine culture and sensitivity  
• vital signs  
• PVR volumes 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 55 GDD-TA-T-004 v2013.9 
 Adverse events will be mapped to a Medical Di ctionary for Regulatory Activities (MedDRA) 
preferred term and system organ classification (SOC) using MedDRA. 
The following analyses will be performed: 
1. Summaries by [CONTACT_742643] [ADDRESS_1015140] investigator assessment of  relation to the IP will be 
assigned to the primary SOC and preferre d term for the appropriate summaries. 
2. All adverse events for indi vidual patients showing both ve rbatim, preferred term, and 
primary SOC 
3. Serious adverse events and adverse events related to the IP, the device constituent 
alone (silicone device/nitinol wire/elastom er components), and th e drug (lidocaine) 
constituent alone; overall summary by [CONTACT_180394], primary SOC, and severity 
4. Serious adverse events  and adverse events  related to the procedure (cystoscopy, IP 
insertion procedure or the IP removal pr ocedure); overall summary and summary by 
[CONTACT_11702], primary SOC, and severity 
5. Descriptive summaries of clinical laboratory  results (see Section 6.5.5 for detailed 
listings of the specific laboratory analytes)  
6. Clinical laboratory abnormality shifts from baseline 
7. Descriptive summaries of vital signs includ ing systolic and diastolic blood pressure, 
heart rate, respi[INVESTIGATOR_697], and body temperature 
8. Descriptive summaries of PVR volume measurements 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 56 GDD-TA-T-004 v2013.9 
 9. Prior and concomitant medication (coded using World Health Organization [WHO]-
Drug Dictionary) 
7.[ADDRESS_1015141] been enrolled.  Missing data will only be imputed for the analysis of the 
primary efficacy variable.  Any deviations to the SAP made after database lock will be 
documented in the final Clinical Study Report. 
7.6 Subgroup Analyses 
There is no pre-planned subgroup analysis.  Any subgroup analysis will be done in an ad hoc 
manner after data base lock. 
7.7 Sample Size Calculation 
Based on the assumption that 5% of the randomized patients will not be evaluable for the 
primary analysis, approximately 76 patients will  be enrolled into the study to ensure 
72 evaluable patients overall.  At a randomizatio n ratio of 2:1:1, 72 evaluable patients will 
ensure that there will be about 36 patients in the LiRIS 400 mg/LiRIS 400 mg group, 
18 patients in the LiRIS Placebo/LiRIS 400 mg  group, and 18 patients in the LiRIS 
Placebo/LiRIS Placebo group. 
A sample size of  36 patients in the LiRIS 400 mg/LiRIS 400 mg group versus 18 patients in 
the LiRIS Placebo/LiRIS Placebo group will have 76% power to detect a difference of 1.[ADDRESS_1015142] deviation is the 
Week 4 Follow-up raw average daily NRS. 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 57 GDD-TA-T-004 v2013.9 
 7.8 Interim Analyses 
After approximately 50% of patients enrolled complete the Treatment [ADDRESS_1015143] been 
enrolled.  If such an interim analysis is to be performed, details of the interim analysis and 
procedures to maintain blinding of treatment groups and confidentiality of results will be 
presented in the SAP. 
8. Study Visit Schedule and Procedures 
Please see Table 1 for the schedule of visits and procedures, Figure 1 for the visit flow chart, 
and Section 6.5 for detailed information on study procedures, tests, equipment, and 
techniques. 
8.1 Patient Entry Procedures  
8.1.1 Overview of Entry Procedures 
Prospective patients as defined by [CONTACT_201976] 4.3 and 4.4 (inclusion/exclusion 
criteria) will be considered for entry into this study. 
8.1.[ADDRESS_1015144] also give authorization (US only) and other written documentation in accordance with 
the relevant country and local privacy requir ements (where applicab le) prior to any study-
related procedures or change in treatment. 
Each patient that provides informed consent and/ or assent will be a ssigned a patient number 
by [CONTACT_54537]/IWRS that will be used on patient documentation throughout the study. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 58 GDD-TA-T-004 v2013.9 
 8.2 Procedures for Final Study Entry 
Final study eligibility will be determined at the Randomization/Day [ADDRESS_1015145] support protocol requirement for 
IC with HL.  In addition, the investigator should confirm that the “day of treatment criteria” 
have been fulfilled (Section 5.8.1).  Patients should continue to meet other inclusion and 
exclusion criteria as specified in Se ctions 4.[ADDRESS_1015146] entered th e study when they are randomized to treatment. 
See Section 5.5 for the method for assignm ent to treatment groups/randomization. 
8.3 Visits and Associated Procedures  
For a summary of the procedures to be perf ormed, see Table 1 (Schedule of Visits and 
Procedures).  A description of individual proced ures is provided in Section 6.5.  The total 
number of clinic visits and study duration fo r each patient will depend on whether patients 
request and qualify for retreatment.  Evaluati ons should be performed by [CONTACT_742644].  During the study, every effort should be made to 
perform the study procedures as indicated in Table 1. 
8.4 Instructions for the Patients 
Patients will be instructed on the following: 
• pain assessment tool and bladder diary completion (Sections 6.5.12 and 6.5.13) 
• complete and bring diaries (electronic and paper) to the study site at each scheduled clinic study visit 
• contact [CONTACT_3452] (or have a family me mber or friend contact [CONTACT_3452]) to 
report any hospi[INVESTIGATOR_602] 
• maintain the dose of any concurrent medicati on.  If there are changes to medications, 
dosage, or frequency, the changes should be reported to the investigator at the next 
study visit. 
• report all usage of rescue medi cations to the investigator at the next study visit (see 
Section 4.5.3) 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 59 GDD-TA-T-004 v2013.9 
 • call the study site if they are experiencing any difficulties following study procedures 
• call the study site as soon as possible in order to reschedule, if the patient cannot 
make their next scheduled study visit 
8.5 Unscheduled Visits 
Unscheduled visits can be performed if safety concerns arise and at  the discretion of the 
investigator.  Additional examinations may be performed as necessary to ensure the safety 
and wellbeing of patients during the study.  eCRFs will be completed for each unscheduled 
visit. 
8.6 Compliance With Protocol 
Participating patients should be able to adhere  to the diary completion and testing parameters 
as described in this protocol. 
Data will be recorded on the appropriate eCRF supported by [CONTACT_555866].  At each visit, patients should be asked if any concomitant medications had 
been used, if they had undergone any concurre nt procedures (nonstudy procedures), and their 
compliance with the protocol since the previous visit. 
8.7 Early Discontinuation of Patients 
Patients may voluntarily withdraw from the study at any time.  If the withdrawal occurs 
during the treatment period in wh ich the IP is in the patient’ s bladder, the patient should 
contact [CONTACT_742645] a visit for IP removal.  If a patient exits the study prior to 
completion, all Exit Visit assessments should be performed at the time of exit. 
Notification of early patient discontinuation from the study a nd the reason for discontinuation 
will be made to Allergan and will be clearly documented on the appropriate eCRF.   
8.[ADDRESS_1015147] the right to withdraw a patient from the study at any time 
for any reason. 
Patients should be discontinued from the study if any of the following criteria are met: 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 60 GDD-TA-T-004 v2013.9 
 • patient develops (or has an exacerbation of ) any medical condition that, in the opi[INVESTIGATOR_8574], would put the patient at an unacceptable medical risk or 
compromises the patient’s ability  to participate in the study 
• patient becomes pregnant (see Section [IP_ADDRESS] for Definition of Females of 
Childbearing Potential and Accep table Contraceptive Methods) 
• patient is unwilling or unable to continue to comply with study procedures   
Where possible, the decision to withdraw a patient from study treatment or the study should 
be discussed with Allergan. 
8.9 Study Termination 
The study may be stopped at his/he r study site at any time by [CONTACT_535394].  Allergan 
may stop the study (and/or the study site) for any reason with appropriate notification. 
9. Adverse Events  
Adverse events occurring during the study will be recorded on an adverse event eCRF.  If adverse events occur, the first concern w ill be the safety of the study participants. 
9.[ADDRESS_1015148] a causal 
relationship with this treatment.  An advers e event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), sympto m, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product.  In additi on, during the Screening period, adverse events 
will be assessed regardless of the administration of a pharmaceutical product. 
Note:  Adverse events must be collected once in formed consent has been obtained, regardless 
of whether or not the patient has been administered study IP. Progression of treatment indicati on including new or worsening of  anticipated clinical signs 
or symptoms, which are collected as clinical efficacy variables and assessed as unequivocally 
associated with the disease progression and/or  lack of efficacy, should NOT be reported as 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 61 GDD-TA-T-004 v2013.9 
 adverse events unless the disease progression is greater than antic ipated in the natural course 
of the disease. 
Adverse events will be assessed, documented, and recorded in the eCRF throughout the study 
(ie, after informed consent has been obtained).  At each visit, the investigator will begin by 
[CONTACT_249616] a general, non-directed question such as 
“How have you been feeling since the last visit?”  Directed questioning and examination will 
then be done as appropriate.  All reported  adverse events will be documented on the 
appropriate eCRF. 
9.1.[ADDRESS_1015149] Infection 
An adverse event of UTI is defined as a UTI based on the investigator’s decision to initiate 
antibiotic treatment (due to results from urine analysis + urine culture or patient’s symptoms 
with appropriate findings in th e urine analysis and culture in  the investigator’s opi[INVESTIGATOR_1649]). 
Note:  If urinalysis/culture results are reported which, in the opi[INVESTIGATOR_871], are 
considered clinically relevant but do not fulfill the above definition of a UTI as no antibiotic 
treatment is initiated by [CONTACT_093], the findings should be recorded as adverse events 
(eg, bacteriuria, leukocyturia).  
9.1.3 Serious Adverse Event 
A serious adverse event is any adverse event oc curring at any dose that results in any of the 
following outcomes:  death, a life-threatening adverse event, inpatient hospi[INVESTIGATOR_249589], a persistent or signifi cant disability/in capacity, or a 
congenital anomaly/birth defect.  Important medi cal events that may not result in death, be 
life-threatening, or require hospi[INVESTIGATOR_3767] a serious adverse event when, 
based upon appropriate medical judgment, they may jeopardize the patient or subject and 
may require medical or surgical intervention to  prevent one of the outcomes listed in this 
definition.  (See Section 9.3 for procedur es for reporting a serious adverse event.) 
Allergan considers all cancer adverse events as serious adverse events.  In addition, Allergan 
considers any abortion (spontaneous or nonspontaneous) as a serious adverse event. 
Pre-planned surgeries or procedures for pre- existing, known medical conditions for which a 
patient requires hospi[INVESTIGATOR_249590] a serious adverse event. 
Any pre-planned surgery or procedure should be clearly documented in the site source 
documents by [CONTACT_249617]’s entry into the 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 62 GDD-TA-T-004 v2013.9 
 study.  If it has not been documented at the time of the patient’s entry into the study, then it 
should be documented as a serious ad verse event and reported to Allergan. 
9.1.[ADDRESS_1015150] be  completed using the following definitions as 
guidelines: 
Mild Awareness of sign or symptom, but easily tolerated. 
Moderate Discomfort enough to cause interference with usual activity. 
Severe Incapacitating with inability to work or do usual activity. Not applicable In some cases, an advers e event may be an “all or nothing” finding 
which cannot be graded. 
 
9.1.[ADDRESS_1015151] or Study 
Procedure 
A determination will be made of the relations hip (if any) between an adverse event and the 
study IP or study procedure, as applicable.  A causal relationship is pres ent if a determination 
is made that there is a reasonable possibility that the adverse event may have been caused by 
[CONTACT_742646].   
9.[ADDRESS_1015152] be recorded on the appropriate eCRF. 
All adverse events that are IP-related and unexpe cted (not listed as treatment-related in the 
current Investigator's Brochure) must be re ported to the governi ng Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) as required by [CONTACT_1201]/IEC, local 
regulations, and the governing he alth authorities.  Any adverse event that is marked 
”ongoing” at the Exit Visit must be followed-up as appropriate. 
9.3 Procedures for Reporting a Serious Adverse Event 
Any serious adverse event occurring during the study period (beginning with informed 
consent) and for at least [ADDRESS_1015153] be immediately reported 
but no later than 24 hours after l earning of a serious adverse even t.  Serious adverse events 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015154] be reported to Allergan (or agent of A llergan) as listed on the Allergan Study Contacts 
Sheet and recorded on the serious adverse even t Form.  All patients with a serious adverse 
event must be followed up and the outcomes reported.  The investigator must supply Allergan 
and the IRB/IEC with any additional request ed information (eg, autopsy reports and 
discharge summaries). 
In the event of a serious advers e event, the investigator must: 
1. Notify Allergan immediately by [CONTACT_687980] 
(contact [CONTACT_249620] 1 of  the serious adverse event form); phone 
numbers and relevant Allergan personnel c ontacts are also on the front page of 
protocol. 
2. Obtain and maintain in his/her files all pe rtinent medical records, information, and 
medical judgments from colleagues who assist ed in the treatment and follow-up of the 
patient. 
3. Provide Allergan with a complete, written description of the adverse event(s) on the 
serious adverse event form describing the event chronologically, including any 
treatment given (eg, medications administer ed, procedures performed) for the adverse 
event(s).  Summarize relevant clinical information about the event:  signs, symptoms, 
diagnosis, clinical course and relevant clin ical laboratory tests, etc.  Include any 
additional or alternative expl anation(s) for the causality which includes a statement as 
to whether the event was or was not relate d to the use of the investigational IP. 
4. Promptly inform the governing IRB/IEC of the serious adverse event as required by 
[CONTACT_1201]/IEC, local regulations, and the governing health authorities. 
9.4 Procedures for Unblinding of Study Medication 
When necessary for the safety and proper trea tment of the patient, the investigator can 
unblind the patient’s treatment assignment to determine which treatment has been assigned 
and institute appropriate follow-up care.  When possible, the sponsor (Allergan Medical 
Safety Physician) should be notified prior to unblinding study medication.  The investigator 
should inform the sponsor (Allergan Medical Safety Physician) of the unblinding if there is no notification prior to the unmasking.   
The treatment assignment for the patient can be determined by [CONTACT_742647].  The reason for 
breaking the code must be recorded in the patient’s source documents. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015155] ance with the applicable  Good Clinical Practice 
(GCP) regulations and guidelines, eg, the In ternational Conference on Harmonisation (ICH) 
Guideline on GCP. 
10.1 Protection of Human Patients 
10.1.1  Compliance With Informed Cons ent Regulations (US 21 Code 
of Federal Regulations [CFR] Pa rt 50) and Relevant Country 
Regulations 
Written informed consent is to be obtained from each patient prior to any study-related 
activities or procedures in the study, and/or from the pa tient's legally authorized 
representative.  If the patient is under the le gal age of consent, the consent form must be 
signed by [CONTACT_535397] w ith the relevant country and 
local regulatory requirements. 
10.1.2  Compliance With IRB or IEC Regulations 
This study is to be conducted in accordance with IRB regulations (US 21 CFR Part 56.103) 
or applicable IEC regulations.  The inves tigator must obtain a pproval from a properly 
constituted IRB/IEC prior to init iating the study and re-approval or review at least annually.  
Allergan is to be notified immediately if the re sponsible IRB/IEC has been  disqualified or if 
proceedings leading to disqualification have begun.  Copi[INVESTIGATOR_28078]/IEC correspondence 
with the investigator should be provided to Allergan. 
10.1.[ADDRESS_1015156] ance with the applicable GCP regulations and 
guidelines.  
10.1.4  Compliance With Electronic Reco rds; Electronic Signatures 
Regulations (US 21 CFR Part 11) 
This study is to be conducted in compliance with the regulations on electronic records and 
electronic signature. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015157] not implement any devia tion from or changes of the protocol without 
approval by [CONTACT_535398]/favorable opi[INVESTIGATOR_120973]/IEC of a protocol amendment, except wher e necessary to eliminate immediate hazards 
to study patients, or when the changes involve on ly logistical or admini strative aspects of the 
study (eg, change in monitors, change of telephone numbers). 
10.3 Patient Confidentiality 
A report of the results of this study may be published or sent to the appropriate health 
authorities in any country in which the study drug may ultimately be marketed, but the 
patient’s name [CONTACT_249626].  The patient's name [CONTACT_742650], Allergan, or the governing health  authorities or the 
Food and Drug Administration (FDA) if they inspect the study records.  Appropriate 
precautions will be taken to maintain confid entiality of medical records and personal 
information. 
10.3.1  Patient Privacy 
Written authorization (US sites only) and other documentation in accordance with the 
relevant country and local privacy requirements (where applicable) is to be obtained from 
each patient prior to enrollment into the study, and/or from the patient's legally authorized 
representative in accordance w ith the applicable privacy re quirements (eg, the Health 
Insurance Portability and A ccountability Act Standards fo r Privacy of Individually 
Identifiable Health Information (“HIPAA”). 
In accordance with HIPAA requirements, additional purposes of this study may include 
publishing of anonymous patient data from the study.  
10.4 Documentation 
10.4.1  Source Documents 
Source documents may include a pa tient's medical records, hospi[INVESTIGATOR_1332], clinic charts, the 
investigator's patient study file s, electronic diaries, as well as the results of diagnostic tests 
such as x-rays, and laboratory tests.  The investigator's copy of  the eCRFs serves as part of 
the investigator's record of a patient's study-related data. 
The following information should be entere d into the patient's medical record: 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 66 GDD-TA-T-004 v2013.9 
 • patient’s name 
• patient’s contact [CONTACT_3031] 
• a statement that informed consent was obtained (including the date).  A statement that 
written authorization (US sites only), or  other country and lo cal patient privacy 
required documentation for this study ha s been obtained (i ncluding the date). 
• the date that the patient was randomized in to the study, patient number, and patient 
medication kit number, and date and details of study IP administration  
• the study title and/or the protocol number of the study and the name [CONTACT_502190] 
• dates of all patient visits and da te of any request for retreatment 
• all concurrent medications (List all pres cription and non-prescription medications 
being taken at the time of enrollment.  At each  subsequent visit, changes to the list of 
medications should be recorded.) 
• all usage of rescue medications 
• occurrence and status of any adverse events (including a ny procedure-related adverse 
events) 
• date the patient exited the study, and a not ation as to whether the patient completed 
the study or reason for discontinuation 
• results of laboratory tests perf ormed by [CONTACT_131355] 
• concurrent procedures performed during the study 
• vital signs and PE findings 
• questionnaire/diary data entered directly onto the appropriate form will be considered 
source data 
10.4.2  Case Report Form Completion 
The investigator is responsible for ensuring that  data are properly recorded on each patient's 
eCRF and related documents.  An investigator who has signed the protocol signature [CONTACT_742651] (as indicated in the eCRF) to ensure that the 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 67 GDD-TA-T-004 v2013.9 
 observations and findings are recorded on the eCRF correctly and completely.  The eCRFs 
are to be submitted to Allergan in a timely manner at the completion of the study, or as 
otherwise specified by [CONTACT_742648] a central data repository. 
10.4.3  Study Summary 
An investigator's summary will be provided to Allergan within a short time after the completion of the study, or as designated by [CONTACT_287447].  A summary is also to be provided to 
the responsible IRB/IEC. 
10.4.[ADDRESS_1015158].  These documents 
should be retained for a longer period, however , if required by [CONTACT_941] a pplicable re gulatory 
requirement(s) or if needed by [CONTACT_78562]. 
In addition, for countries not falling within th e scope of the ICH guidelines, local regulatory 
requirements should be followed regarding the re tention of clinical study documentation. 
Allergan requires that it be notified in writi ng if the investigator wishes to relinquish 
ownership of the data so that mutually agreed-u pon arrangements can be made for transfer of 
ownership to a suitably qua lified, responsible person. 
10.5 Labeling, Packaging, and Return or Disposal of Study 
Medications/Treatments 
10.5.1  Labeling/Packaging 
Each LiRIS (both active and placebo) is provided sterile and in an individually labeled Tyvek 
sealed pouch.  The pouch is placed into a s econdary, standard pape r based carton stock, 
which is labeled with a standard adhesive back ed paper label containi ng appropriate clinical 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015159] supervisi on of an investigator.  A unit is defined as one LiRIS. 
10.5.3  Return or Disposal of Study Medications/Treatments and/or 
Supplies 
All clinical study medications/treatments and/or  supplies will be returned to Allergan or 
Allergan designee for destruction. 
Each LiRIS removed from the bladder of a study pa tient will be retained and sent to Allergan 
for a post-use assessment.  Detailed instructi ons for the storage and shipment of LiRIS post-
removal are provided in the Study Manual. 
10.[ADDRESS_1015160] 
on-site visits to review, audit and copy study- related documents.  These representatives will 
meet with the investigator(s) and appropriate staff at mutua lly convenient times to discuss 
study-related data and questions. 
10.7 Handling of Biological Specimens  
Blood and urine samples will be analyzed for lidocaine and 2,6-xylidine concentrations 
(pharmacokinetics) at a bioanalytical la boratory that meets GLP requirements. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 69 GDD-TA-T-004 v2013.9 
 Samples of blood and urine specified in Section 6.5 will be analyzed at a central laboratory 
with certification from a r ecognized accreditation agency (eg, College of American 
Pathology [CAP] or Clinical Laboratory Improve ment Amendments [CLIA] certification).    
The Central Laboratory Manual provides de tails regarding labor atory collection and 
shipment procedures for blood and urine samples in this study. 
Allergan shall have full ownership rights to any biological samples derived from the study. 
10.[ADDRESS_1015161] joint cooperation betw een multiple investig ators and sites and 
Allergan personnel.  Authorship will be establis hed prior to the writing of the manuscript.  As 
this study involves multiple centers, no individu al publications will be allowed prior to 
completion of the final report of the multicen ter study except as agreed with Allergan. 
10.9 Coordinating Investigator 
A signatory Coordinating Investigator [INVESTIGATOR_535354]. 
11. References 
Berry SH, Bogart LM, Pham C, Liu K, Nyberg L, Stoto M, et al. Development, validation 
and testing of an epi[INVESTIGATOR_742617]/painful bladder 
syndrome. J Urol. 2010 May;183(5):1848-1852. 
Berry SH, Elliott MN, Suttorp M, Bogart LM, St oto MA, et al. Prevalence of symptoms of 
bladder pain syndrome/interstitia l cystitis among adult females in the [LOCATION_002]. J Urol 
2011;186:540-544. 
Birch BR, Miller RA. Absorption characteris tics of lignocaine following intravesical 
instillation. Scand J Urol Nephrol. 1994;28(4):359-364. Brazier JE. The Short-Form 36 (SF-36) Health Survey and its use in pharmacoeconomic 
evaluation. Pharmacoeconomics. 1995 May;7(5):403-415. Review. 
Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 70 GDD-TA-T-004 v2013.9 
 Cassuto J, Sinclair R, Bonderovic M. Anti-infl ammatory properties of local anesthetics and 
their present and potential clin ical implications. Acta An aesthesiol Scand. 2006;50(3):265-
282. 
Chancellor MB and Yoshimura N. Treatment of  interstitial cy stitis. Urology. 2004;Mar;63([ADDRESS_1015162] 1):85-92. Fall M, Logadottir Y , Peeker R. Interstitial cy stitis is bladder pain syndrome with Hunner's 
lesion. Int J Urol. 2014;21(Suppl 1):79-82. Hanno P, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, FitzGerald MP, et al.  
Diagnosis and treatment of inte rstitial cystitis/bladder pain syndrome.  American Urological 
Association (AUA) Guideline. 2014:1-45. 
Henry R, Patterson L, Avery N, Tanzola R, Tod D, Hunter D, et al. Absorption of alkalized 
intravesical lidocaine in normal and inflam ed bladders: a simple method for improving 
bladder anesthesia. J Urol . 2001;165(6 Pt 1):1900-1903. 
Higson RH, Smith JC, Hills W. Intravesical li gnocaine and detrusor instability. Br J Urol. 
1979;51(6):500-503. 
Killinger KA, Boura JA, Peters KM.  Pain in in terstitial cystitis/bladder pain syndrome: do 
characteristics differ in ulcerative and non-ulcerative subtypes?  Int Urogynecol J. 
2012:s00192-012-2003-9. 
Logadottir Y , Delbro D, Lindholm C, Fall M, Peeker R. Inflammation characteristics in 
bladder pain syndrome ESSIC type 3C/cla ssic interstitial cystitis. Int J Urol. 
2014;21(Suppl 1):75-78. 
Logadottir Y , Fall M, Kabjorn-Gustafsson C, P eeker R.  Clinical characteristics differ 
considerably between phenotypes of bladder pain  syndrome/interstitial cy stitis. Scand J Urol 
Nephrol. 2012: early online, 1-6. Lidoderm. Lidocaine Patch 5%. Prescrib ing Information. Malvern, PA: Endo 
Pharmaceuticals Inc.; 2013. Meijlink JM.  Interstitial cystitis and the painful bladder: a brief history of nomenclature, 
definitions and criteria. Int J Urol. 2014;21(Suppl 1):4-12. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 71 GDD-TA-T-004 v2013.9 
 Nakahara T, Moriuchi H, Tanaka Y , Yunoki M, Kubota Y , Sakamato K, et al. Role of K+ 
Channels in N-acetylprocainamide-induced rela xation of bovine tracheal smooth muscle. Eur 
J Pharmacol. 2001;415:73-78. 
Nickel JC, Moldwin R, Lee S, Davis EL, He nry RA, Wyllie MG. Intravesical alkalinized 
lidocaine (PSD597) offers sustained relief from symptoms of interstitial  cystitis and painful 
bladder syndrome. BJU Int. 2008;103(7):910-918. 
Nordling J, Fall M, Hanno P.  Global concepts of bladder pain syndrome (int erstitial cystitis).  
World J Urol. 2012;30:457-464. Olsen PC, Ferreira TPT, Serra MF, Farias-Filho FA, Fonseca BP, Viola JPB, et al. Lidocaine-
derivative JMF2-[ADDRESS_1015163] inflammation by [CONTACT_742649] T cells. Clinical  and Experimental Allergy. 2011;41:250-259. 
Olsen PC, Coelho LP, da Costa JCS, Cordeiro RSB, Silva PMR, Martins MA. Two for one: 
Cyclic AMP mediates the anti-inflammatory  and anti-spasmodic properties of the non-
anesthetic lidocaine analog JMF2-1. Eur J Pharmacol. 2012;680:102-107. 
O’Leary MP, Sant GR, Fowler FJ, Whitmore KE, S polarich-Kroll J. The Interstitial Cystitis 
Symptom Index and Problem Index. Urology. 1997;49(Suppl 5A):58-63. 
Parsons CL. Successful downregulation of blad der sensory nerves with combination of 
heparin and alkalinized lidocaine  in subjects with in terstitial cystitis. Urology. 2005;65(1):45-
48. 
Suskind AM, Berry SH, Ewing BA, Elliott MN, Suttorp MK, Clemens JQ. The Prevalence 
and overlap of Interstitial Cystitis/Bladder Pain Syndrome and Chronic Prostatitis/Chronic 
Pelvic Pain Syndrome in men: Results of the RAND Interstitial Cystitis Epi[INVESTIGATOR_742618]. J Urol. 2013;189:141-145. 
van de Merwe JP, Nordling J, Bouchelouche P, B ouchelouche K, Cervigni M, Daha LK, et al. 
Diagnostic criteria, classification, and nomenclature for painful bladde r syndrome/interstitial 
cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60-67. 
Wild D, Grove A, Martin M, Eremenco S, Mc Elroy S, Verjee-Lorenz A, et al. ISPOR Task 
Force for Translation and Cultural Adaptation. Principles of good practice for the translation 
and cultural adaptation process for Patient-Repor ted Outcomes (PRO) measures: report of the 
ISPOR Task Force for Translation and Cultura l Adaptation. Value Health. 2005;8(2):94-104. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 72 GDD-TA-T-004 v2013.9 
 Xylocaine (lidocaine HCl Injection, USP), Xylocaine (lidocaine HCl and epi[INVESTIGATOR_742619], USP), for infiltration and nerve block. Package Insert. Schaumberg, IL: APP 
Pharmaceuticals, LLC. 2010. 
Yokoyama O, Ishiura Y , Nakamura Y , Kunimi K, Mita E, Namiki M. Urodynamic effects of 
intravesical instillation of lidocaine in patients with overactive detrusor. J Urol. 
1997;157(5):1826-1830. 
Yokoyama O, Komatsu K, Kodama K, Yotsuyanagi S, Niikura S, Namiki M. Diagnostic 
value of intravesical lidocaine for ov eractive bladder. J Urol. 2000;164(2):340-343. 
Yunoki M, Nakahara T, Mitani A, Maruko T,  Kubota Y , Sakamoto K, et al. Lidocaine 
attenuates muscarinic receptor-mediated inhi bition of adenylyl cyclase in airway smooth 
muscle. Eur J Pharmacol. 2003;470:65-71. 
 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 73 GDD-TA-T-004 v2013.9 
 12. Attachments 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 74 GDD-TA-T-004 v2013.9 
 12.1 Questionnaires 
12.1.1  Overview 
Patient questionnaires will be: 
• administered to all patients in the study prior to having any study procedure 
performed 
• completed only by [CONTACT_102], using a blue or black ballpoint pen on a firm writing 
surface 
• administered in a quiet place with ampl e time for the patient to complete the 
questionnaire 
• filled out completely by [CONTACT_1962] (every question must be answered) 
• completed only at protocol-specified study visits (no attempt should be made at any 
subsequent visit to administer missed questionnaires) 
• a source document; please do not make or use any photocopi[INVESTIGATOR_342933] 
• checked for completeness, and not content, in the patient’s presence - study site personnel should not change re sponses on the questionnaires 
• administered only in countries where the scale has been appropriately culturally 
adapted in local languages as per the In ternational Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) Principles  of Good Practice for the Translation and 
Cultural Adaptation Process for Patient Reported Outcomes Measures (Wild et al, 2005 ).  The versions of the questionnaires provided in the protocol are 
samples and will be replaced with the appropr iate versions for the country where the 
questionnaire will be administered. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 75 GDD -
TA-T-004 v2013.9 
 

 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 76 GDD -
TA-T-004 v2013.9 
 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 77 GDD-TA-T-004 v2013.9 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 78 GDD-TA-T-004 v2013.9 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 79 GDD -
TA-T-004 v2013.9 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 80 GDD -
TA-T-004 v2013.9 
 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 81 GDD -
TA-T-004 v2013.9 
 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 82 GDD-TA-T-004 v2013.9 
 12.2 Handling of Biological Specimens  
Details relating to the handling of biological samples are provided in the Central Laboratory 
Manual. 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 83 GDD-TA-T-004 v2013.9 
 12.3 Glossary of Abbreviations 
Term/Abbreviation Definition 
ALT alanine aminotransferase (SGPT) 
ANCOV A analysis of covariance 
AST aspartate aminotransferase (SGOT) 
AUA American Urological Association 
β-HCG beta-human chorionic gonadotropin 
BPS bladder pain syndrome 
CFR Code of Federal Regulations 
eCRF electronic case report form 
EDC electronic data capture 
  
ESSIC European Society for the Study of IC 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
GGT gamma glutamyltransferase 
GLP Good Laboratory Practice 
HEENT head, ears, eyes, nose, and throat 
HIPAA Health Insurance Portab ility and Accountability Act 
HL Hunner’s Lesion 
HRQoL health-related quality of life 
IC interstitial cystitis 
ICH International Conference on Harmonisation  
  
  
IEC Independent Ethics Committee 
IP Investigational Product 
IRB Institutional Review Board 
ITT intent-to-treat 
IL-1β interleukin-1 beta 
IV intravenous 
IVRS interactive voice response system 
IWRS interactive web response system 
LiRIS lidocaine-releasing intravesical system 
MCH mean corpuscular hemoglobin 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 84 GDD-TA-T-004 v2013.9 
 Term/Abbreviation Definition 
MCHC mean corpuscular hemoglobin concentration 
MCP-1/CCL2 monocyte chemotactic protein [ADDRESS_1015164]-void residual 
RBC red blood cells 
SAP Statistical Analysis Plan 
    
SGOT serum glutam
ic oxaloacetic transaminase 
SGPT serum glutamic pyruvic transaminase 
SOC system organ class 
Tx 1 Treatment 1 Period 
Tx 2 Treatment 2 Period  
US(A) [LOCATION_002] (of America) 
USP [LOCATION_002] Pharmacopeial Convention 
UTI urinary tract infection 
WBC white blood cells 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 85 GDD-TA-T-004 v2013.9 
 12.4 Protocol Amendment 1 Summary  
Title:  A Multicenter, Randomized, Double-bl ind, Placebo-controlled Study, Evaluating 
 Safety and Efficacy of LiRIS® 400 mg in Females With In terstitial Cystitis With 
 Hunner’s Lesions 
Protocol 201025-001 Amendment 1 
Date of Amendment:  February 2015 
Amendment Summary 
This summary includes changes made to Protocol 201025-001 (20 January 2015).  This 
protocol was amended to delete the instructions  for insertion and rem oval of Investigational 
Product (IP) from the protocol.  The direc tions for IP use will be included in the 
Study Manual.   
Following is a summary of content-oriented changes that were made to each section of the protocol, and a brief rationale for these change s.  Minor editorial a nd document formatting 
revisions have not been summarized. 
Section Revision Rationale 
Section 5.8/Treatment 
Administration and 
Section 6.6.11/Insertion and Removal of IP Revised the reference for instructions on 
insertion and removal of IP to 
Study Manual instead of protocol Attachment 12.1 The instructions for IP use are 
being included in the Study 
Manual instead of as an attachment to the protocol 
Section 7.3.3/Safety Analyses # 5:  Deleted the detailed list of specific 
laboratory analytes for which descriptive 
summaries will be provided The list of laboratory analytes 
are included in 
Section 6.6.5
/Clinical 
Laboratory Assessments.  A 
reference has been provided 
to Section 6.6.5.  
Section 7.3.3/Safety 
Analyses, 
Section 10.4.1/Source 
Documents Deleted electrocardiogram (ECG) ECG will not be assessed 
during this study  
Section 12.1/ 
Investigational Product 
Directions for Use Deleted Attachment 12.[ADDRESS_1015165] Directions for Use including 
Attachment 12.1.1 Directions for Insertion of LiRIS
® 400 mg and LiRIS® 
Placebo and Attachment 12.1.2 Directions for Removal of LiRIS
® 400 mg and 
LiRIS® Placebo The instructions for IP use are 
being included in the Study 
Manual instead of as an attachment to the protocol.  Succeeding attachment numbers were adjusted 
accordingly. 
 
 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-001 Amendment 2 
 
 86 GDD-TA-T-004 v2013.9 
 12.5 Protocol Amendment 2 Summary 
Title:  A Multicenter, Randomized, Double-bl ind, Placebo-controlled Study, Evaluating 
 Safety and Efficacy of LiRIS® 400 mg in Females With In terstitial Cystitis With 
 Hunner’s Lesions 
Protocol 201025-001 Amendment 2 
Date of Amendment:  April 2016 
Amendment Summary 
This summary includes changes made to Protocol 201025-001 Amendment 1 
(February 2015).  This protocol was amended to expand entry criteria to increase the rate of 
enrollment. 
Following is a summary of content-oriented changes that were made to each section of the 
protocol, and a brief rationale for these change s.  Minor editorial a nd document formatting 
revisions have not been summarized. 
Section Revision Rationale 
Summary, Table 1, Sections 
6.3, 6.6.7, 7.5, 10.7   
 
Summary, Sections 3, 4.1, 7.7 Sample size of estimated 
evaluable population was 
increased Revision based on results of 
Study TAR-100-105 
Summary, Sections 4.2, 4.3 AUA guidelines were replaced 
with ESSIC (van de Merwe et 
al, 2008) in diagnostic criteria Clarification of diagnostic 
criteria: ESSIC requires 6 
months of symptoms before confirmed diagnosis, consistent with protocol (AUA requires 6 
weeks) 
Table 2, Section 4.4 Period off medication/treatment 
before screening was reduced 
for Elmiron and Botulinum toxin for genitourinary 
treatment There is no indication of any 
increased risk resulting from 
this change based on previous 
LiRIS studies 
Section 4.1 Increased number of study sites Increase enrollment 
Section 4.4 Cardiac & pelvic pain exclusion 
criteria were generalized to specify investigator judgment There is no indication of any 
increased risk resulting from 
this change based on previous 
LiRIS studies 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015166] been trained on 
Sections 7.2  and [IP_ADDRESS] Included imputation for primary 
analysis Patients that have values close 
to the primary timepoint can 
now be included in the primary 
analysis 
Section 7.2.[ADDRESS_1015167] 

 
 
Approval Date :  
 28-Apr-2016Allergan Confidential  Protocol 201025-[ADDRESS_1015168] exploratory nature of 
the study 
Section [IP_ADDRESS] Clarified that no imputation 
method will be used for secondary efficacy variables 
analysis Clarification 
Sections [IP_ADDRESS] and [IP_ADDRESS] Clarified the treatment arms to 
be compared Clarification 
Section 7.3.[ADDRESS_1015169] database lock 
Section 7.7 Corrected the sample size 
derivation Clarification 
Section 7.8 Added that blinded sample size 
estimation may be conducted. 
Clarified when a potential 
interim analysis may occur. Clarification 
 
 
 
Approval Date :  
 28-Apr-2016ALLERGAN  
 
 
 
 
    
 
Date (DD/MMM/YYYY)/Time (PT)  Signed by:  [CONTACT_325766] 201025-001 Amendment 2
